<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PREMPHASE - conjugated estrogens and medroxyprogesterone acetate 
			 </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use PREMPRO/PREMPHASE safely and effectively. See full prescribing information for PREMPRO/PREMPHASE.<br><br>PREMPRO<span class="Sup">®</span> (conjugated estrogens/medroxyprogesterone acetate tablets) <br>PREMPHASE<span class="Sup">®</span> (conjugated estrogens plus medroxyprogesterone acetate tablets)<br>Initial U.S. Approval: 1995</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<br><h1 class="Warning"><span class="Bold"><span class="Bold Italics">See full prescribing information for complete Boxed Warning.</span></span></h1>
<br><p class="Highlighta"><span class="Bold"><span class="Bold Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<ul class="Disc">
<li><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>, <a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
<li><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>)</span></li>
<li><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)</span></li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
</ul>
<br><p class="Highlighta"><span class="Bold"><span class="Bold Underline">Estrogen-Alone Therapy</span></span> </p>
<ul class="Disc">
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)</span></li>
<li><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>, <a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
<li><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>)</span></li>
<li><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="Gfab12e13-0ee9-4227-a34e-77415bf60f5a"></a><table border="1" frame="border">
<colgroup>
<col>
<col>
</colgroup>
<tbody class="Headless"><tr>
<td>Contraindications (4)</td>
<td align="right">05/2010</td>
</tr></tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<br><h1 class="Warning"><span class="Bold"><span class="Bold Italics">See full prescribing information for complete Boxed Warning.</span></span></h1>
<br><p class="Highlighta"><span class="Bold"><span class="Bold Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<ul class="Disc">
<li><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>, <a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
<li><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>)</span></li>
<li><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)</span></li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
</ul>
<br><p class="Highlighta"><span class="Bold"><span class="Bold Underline">Estrogen-Alone Therapy</span></span> </p>
<ul class="Disc">
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)</span></li>
<li><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>, <a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
<li><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>)</span></li>
<li><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">PREMPRO/PREMPHASE is an estrogen/progestin indicated in women with intact uteri for: </p>
<ul class="Disc">
<li>Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> (<a href="#G98d65d30-0b63-498a-b60b-c6459e18d248">1.1</a>)</li>
<li>Treatment of Moderate to Severe Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> (<a href="#G87885c2c-ab90-486b-b960-784df78ae667">1.2</a>)</li>
<li>Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> (<a href="#G801a7ab8-f168-45dd-842e-2c9f74f29906">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">PREMPRO: one tablet containing conjugated estrogens (CE) plus medroxyprogesterone acetate (MPA) taken orally once daily (<a href="#Gd6b0c490-0f08-40f6-9c97-b41cd490c91a">2</a>). </p>
<br><p class="Highlighta">PREMPHASE: one maroon tablet containing 0.625 mg CE taken orally on days 1 through 14, and one light-blue tablet containing 0.625 mg CE plus 5.0 mg MPA taken orally on days 15 through 28 (<a href="#Gd6b0c490-0f08-40f6-9c97-b41cd490c91a">2</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">PREMPRO Tablets (not scored): 0.3 mg CE plus 1.5 mg MPA, 0.45 mg CE plus 1.5 mg MPA, 0.625 mg CE plus 2.5 mg MPA, 0.625 mg CE plus 5 mg MPA.  (<a href="#section-3">3</a>)</p>
<br><p class="Highlighta">PREMPHASE Tablets (not scored): 0.625 mg CE, 0.625 mg CE plus 5 mg MPA.  (<a href="#section-3">3</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>)</li>
<li>Known, suspected, or history of breast cancer (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>, <a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)</li>
<li>Known or suspected estrogen-dependent neoplasia (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>, <a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or a history of these conditions (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>, <a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>)</li>
<li>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) or a history of these conditions (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>, <a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>)</li>
<li>Known liver dysfunction or disease (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>, <a href="#G4c532e7a-a657-4924-b1d6-a768e7279446">5.10</a>)</li>
<li>Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency) (4)</li>
<li>Known or suspected pregnancy (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>, <a href="#Gc6a38475-cc42-498a-87f4-3e8f36f867c5">8.1</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Estrogens increase the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> (<a href="#G54e05570-8def-4fc1-9156-8220d4b1a5e9">5.4</a>)</li>
<li>Discontinue estrogen if severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs (<a href="#Gddda4c95-d986-4ef1-9e7d-811ebb453141">5.5</a>, <a href="#Gf0283836-1969-473c-8971-fe959b7e285b">5.6</a>, <a href="#Ge5d318bc-838b-4918-a46c-c8016aedfdd4">5.9</a>, <a href="#G4c532e7a-a657-4924-b1d6-a768e7279446">5.10</a>)</li>
<li>Monitor thyroid function in women on thyroid replacement therapy (<a href="#Ga7514fed-682e-474d-8566-c59f00156e53">5.11</a>, <a href="#Gaada22aa-e943-4c95-8f42-030a0f25608a">5.18</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In a prospective, randomized, placebo-controlled, double-blind study, the most common adverse reactions ≥ 5 percent are: <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, vaginal monoliasis, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> (<a href="#G035981b2-cc74-422a-93d3-cc69fc8c6bec">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-934-5556 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism (<a href="#G994a5c2a-1bb0-4fef-a081-f55ed8cbf52f">7</a>)</li>
<li>Aminoglutethimide administered concomitantly with MPA may significantly depress the bioavailability of medroxyprogesterone acetate (<a href="#G994a5c2a-1bb0-4fef-a081-f55ed8cbf52f">7</a>)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Nursing Women: Estrogen administration to nursing women has been shown to decrease the quantity and quality of breast milk (<a href="#G7fd487b1-7d7d-4f97-abe4-ed74b04bfc95">8.3</a>)</li>
<li>Geriatric Use: An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women’s Health Initiative Memory ancillary studies of the Women’s Health Initiative (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>, <a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 11/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Treatment of Moderate to Severe Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Malignant Neoplasms</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Visual Abnormalities</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Elevated Blood Pressure</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Exacerbation of Other Conditions </a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Laboratory Tests </a></h2>
<h2><a href="#section-5.18" class="toc">5.18 Drug-Laboratory Test Interactions </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Study Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Metabolic Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Effects on Vasomotor Symptoms</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Effects on Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Effects on the Endometrium</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Effects on Bone Mineral Density</a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Women's Health Initiative Studies</a></h2>
<h2><a href="#section-13.7" class="toc">14.7 Women's Health Initiative Memory Study</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied </a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Possible Serious Adverse Reactions With Estrogen Plus Progestin Therapy</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Possible Less Serious But Common Adverse Reactions With Estrogen Plus Progestin Therapy</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<p class="First"><span class="Bold"><span class="Bold Underline">Estrogen Plus Progestin Therapy</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Bold Italics">[see Warnings and Precautions (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>, <a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>), and Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>, <a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</span></p>
<p><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo <span class="Bold Italics">[see Warnings and Precautions (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>), and Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>)]</span>.</span></p>
<p><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Bold Italics">[see Warnings and Precautions (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>), Use in Specific Populations (<a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a>), and Clinical Studies (<a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</span></p>
<p><span class="Bold">Breast Cancer</span></p>
<p><span class="Bold">The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer <span class="Bold Italics">[see Warnings and Precautions (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>), and Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>)]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.</span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
<p><span class="Bold"><span class="Bold Underline">Estrogen-Alone Therapy</span></span></p>
<p><span class="Bold">Endometrial Cancer</span></p>
<p><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Bold Italics">[see Warnings and Precautions (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Bold Italics">[see Warnings and Precautions (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>, <a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>), and Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>, <a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</span></p>
<p><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg), relative to placebo <span class="Bold Italics">[see Warnings and Precautions (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>), and Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>)]</span>.</span></p>
<p><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Bold Italics">[see Warnings and Precautions (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>), Use in Specific Populations (<a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a>), and Clinical Studies (<a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.</span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Ge83abeeb-a1d2-4b4c-bbbf-c5514b30d339"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="G98d65d30-0b63-498a-b60b-c6459e18d248"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G87885c2c-ab90-486b-b960-784df78ae667"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Treatment of Moderate to Severe Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G801a7ab8-f168-45dd-842e-2c9f74f29906"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Gd6b0c490-0f08-40f6-9c97-b41cd490c91a"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Gdc66770d-88d6-4713-b84c-8dd637961637"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information</h2>
<p class="First">Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gce4843a9-87ba-4a76-86cf-530070240bee"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<p class="First">PREMPRO therapy consists of a single tablet to be taken orally once daily.</p>
<p>PREMPHASE therapy consists of two separate tablets: one maroon 0.625 mg Premarin (conjugated estrogens) tablet taken daily on days 1 through 14 and one light-blue tablet containing 0.625 mg conjugated estrogens and 5 mg of medroxyprogesterone acetate taken on days 15 through 28.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gb958b054-4d56-4046-9485-4b90963ef267"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Treatment of Moderate to Severe Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<p class="First">PREMPRO therapy consists of a single tablet to be taken orally once daily.</p>
<p>PREMPHASE therapy consists of two separate tablets: one maroon 0.625 mg Premarin [conjugated estrogens (CE)] tablet taken daily on days 1 through 14 and one light-blue tablet containing 0.625 mg CE and 5 mg of medroxyprogesterone acetate (MPA) taken on days 15 through 28.</p>
<p>When prescribing solely for the treatment of moderate to severe vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ga1f57821-ff7c-451d-8c9b-a2b46453161a"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First">PREMPRO therapy consists of a single tablet to be taken orally once daily.</p>
<p>PREMPHASE therapy consists of two separate tablets: one maroon 0.625 mg Premarin (conjugated estrogens) tablet taken daily on days 1 through 14 and one light-blue tablet containing 0.625 mg conjugated estrogens and 5 mg of medroxyprogesterone acetate taken on days 15 through 28.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="G31df1595-b55f-4d67-9101-d1dfc779a234"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<a name="Gb3617226-dc17-46bf-a5a6-cac7bcaa7dd1"></a><table border="1" frame="border">
<colgroup>
<col width="204px">
<col width="208px">
<col width="208px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom"><th align="center" colspan="3" valign="bottom">PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets)</th></tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="middle">Tablet Strength</td>
<td align="center" valign="middle">Tablet Shape/Color</td>
<td align="center" valign="middle">Imprint</td>
</tr>
<tr>
<td align="center">0.3 mg CE plus 1.5 mg MPA</td>
<td align="center">oval / cream</td>
<td align="center">PREMPRO<br>0.3/1.5 </td>
</tr>
<tr>
<td align="center">0.45 mg CE plus 1.5 mg MPA</td>
<td align="center">oval / gold</td>
<td align="center">PREMPRO<br>0.45/1.5 </td>
</tr>
<tr>
<td align="center">0.625 mg CE plus 2.5 mg MPA</td>
<td align="center">oval / peach</td>
<td align="center">PREMPRO<br>0.625/2.5</td>
</tr>
<tr>
<td align="center">0.625 mg CE plus 5 mg MPA</td>
<td align="center">oval / light blue</td>
<td align="center">W<br>0.625/5</td>
</tr>
<tr><td align="center" colspan="3">PREMPHASE (conjugated estrogens/medroxyprogesterone acetate tablets)</td></tr>
<tr>
<td align="center">Tablet Strength</td>
<td align="center">Tablet Shape/Color</td>
<td align="center">Imprint</td>
</tr>
<tr>
<td align="center">0.625 mg CE</td>
<td align="center">oval / maroon (14 tablets)</td>
<td align="center">PREMARIN<br>0.625</td>
</tr>
<tr class="Last">
<td align="center">0.625 mg CE plus 5 mg MPA</td>
<td align="center">oval / light-blue (14 tablets)</td>
<td align="center">W<br>0.625/5 </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="G272f4123-7baa-4a22-95c5-7195ee6b55bd"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">PREMPRO or PREMPHASE therapy should not be used in women with any of the following conditions:</p>
<ul class="Disc">
<li><span class="Bold">Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></li>
<li><span class="Bold">Known, suspected, or history of breast cancer</span></li>
<li><span class="Bold">Known or suspected estrogen-dependent neoplasia</span></li>
<li><span class="Bold">Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or a history of these conditions</span></li>
<li><span class="Bold">Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>), or a history of these conditions</span></li>
<li><span class="Bold">Known liver dysfunction or disease</span></li>
<li style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency)</span></span></li>
<li><span class="Bold">Known or suspected pregnancy</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="G6b9182cc-a83e-4358-b088-927762dd73b2"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="G4a357322-b1d8-4c07-b3fc-9b870b5eabef"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">An increased risk of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been reported with estrogen plus progestin therapy. An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogens with or without progestins should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (for example, personal history of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> [VTE], <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="G630b3650-00a1-4d0b-a5d2-5630771dea84"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></h3>
<p class="First">In the Women's Health Initiative (WHI) estrogen plus progestin substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in all women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to placebo (33 versus 25 per 10,000 women-years) <span class="Italics">[see Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>)]</span>. The increase in risk was demonstrated after the first year and persisted.<span class="Sup">1</span> Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</p>
<p>In the WHI estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year one and persisted <span class="Italics">[see Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>)]</span>.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for those women receiving CE (0.625 mg) versus those receiving placebo (18 versus 21 per 10,000 women-years).<span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G784cbfae-86ad-4b8d-8bb9-3e44b7f2512d"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="Italics">Coronary Heart Disease</span></h3>
<p class="First">In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).<span class="Sup">1</span> An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 <span class="Italics">[see Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>)]</span>.</p>
<p>In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> [MI], silent MI, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was reported in women receiving estrogen-alone compared to placebo<span class="Sup">2</span><span class="Italics"> [see Clinical Studies (</span><span class="Italics"><a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a></span><span class="Italics">)]</span>.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE 0.625 mg compared to placebo) in women with less than 10 years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (8 versus 16 per 10,000 women-years).<span class="Sup">1</span></p>
<p>In postmenopausal women with documented heart disease (n = 2,763), average age 66.7 years, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE (0.625 mg) plus MPA (2.5 mg) group and the placebo group in HERS, HERS II, and overall.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gf9ab23c0-5c74-4960-af71-e05e4adf3f40"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> (VTE)</span></h3>
<p class="First">In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE (DVT and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> [PE]) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted<span class="Sup">3</span><span class="Italics"> [see Clinical Studies (</span><span class="Italics"><a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a></span><span class="Italics">)]</span>. Should a VTE occur or be suspected, estrogens should be discontinued immediately.</p>
<p>In the WHI estrogen-alone substudy, the risk of VTE (DVT and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> [PE]) was increased for women receiving daily CE (0.625 mg) compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years<span class="Sup">4</span><span class="Italics"> [see Clinical Studies (</span><span class="Italics"><a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a></span><span class="Italics">)]</span>. </p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gdc16a52e-8a04-4cc6-8d43-09aa530591a4"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Malignant Neoplasms</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="G286c9e5d-af66-48d5-bb84-502d2bd64f45"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="Italics">Endometrial Cancer</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> (a possible precursor of endometrial cancer) has been reported to occur at a rate of approximately 1 percent or less with PREMPRO or PREMPHASE. </p>
<p>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears to be associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G05bbef7d-47f2-461c-9b6b-3808b59b9658"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="Italics">Breast Cancer</span></h3>
<p class="First">The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the Women's Health Initiative (WHI) substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin WHI substudy reported an increased risk of breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for estrogen plus progestin compared with placebo.<span class="Sup">5</span> Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for estrogen plus progestin compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for estrogen plus progestin compared with placebo. In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups <span class="Italics">[see Clinical Studies (<a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a>)]</span>.</p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the Women's Health Initiative (WHI) substudy of daily CE (0.625 mg). In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE (0.625 mg) was not associated with an increased risk of invasive breast cancer <span class="Italics">[relative risk (RR) 0.80]</span><span class="Sup">6</span><span class="Italics"> [see Clinical Studies (</span><span class="Italics"><a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a></span><span class="Italics">)]</span>.</p>
<p>Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.</p>
<p>The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation.</p>
<p>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ga7b94c4f-051d-489d-8e34-d37d91ac076a"></a><a name="section-5.2.3"></a><p></p>
<h3><span class="Italics">Ovarian Cancer</span></h3>
<p class="First">The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent nCI 0.77-3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.<span class="Sup">7</span> In some epidemiologic studies, the use of estrogen-plus progestin and estrogen-only products has been associated with an increased risk of ovarian cancer over multiple years of use. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies, and some report no association.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G30aad6c8-10b4-4bee-b479-27fe6299a518"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the estrogen plus progestin Women’s Health Initiative Memory Study (WHIMS), an ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.</p>
<p>In the WHIMS estrogen plus progestin ancillary study, after an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent nCI 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years<span class="Sup">8 </span><span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a></span><span class="Italics">), and Clinical Studies (</span><span class="Italics"><a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</p>
<p>In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg) or placebo.</p>
<p>In the WHIMS estrogen-alone ancillary study, after an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent nCI 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years<span class="Sup">8</span><span class="Italics">[see Use in Specific Populations (<a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a>), and Clinical Studies (<a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</p>
<p>When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent nCI 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8</span><span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a></span><span class="Italics">), and Clinical Studies (</span><span class="Italics"><a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G54e05570-8def-4fc1-9156-8220d4b1a5e9"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></h2>
<p class="First">A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gddda4c95-d986-4ef1-9e7d-811ebb453141"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in women with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gf0283836-1969-473c-8971-fe959b7e285b"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Visual Abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd58b9478-dd76-4fcc-bdff-bec81a2687d3"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</h2>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G64543573-afdd-4545-b335-5e99b78e2508"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Elevated Blood Pressure</h2>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ge5d318bc-838b-4918-a46c-c8016aedfdd4"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">In women with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Consider discontinuation of treatment if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G4c532e7a-a657-4924-b1d6-a768e7279446"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></h2>
<p class="First">Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ga7514fed-682e-474d-8566-c59f00156e53"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G9e374255-a91f-4073-b8fe-72945b2b9f94"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Estrogens plus progestins may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Women with conditions that might be influenced by this factor, such as cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gf09e1444-01f8-4719-99d5-b6e426fa0aae"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First">Estrogen therapy should be used with caution in women with <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> as estrogen-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G94dfce08-0418-4681-89e2-47c2d557f951"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></h2>
<p class="First">A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G7aaea6bd-1f0e-4e67-a206-f31f0978cc2d"></a><a name="section-5.15"></a><p></p>
<h2>5.15 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h2>
<p class="First">Exogenous estrogens may induce or exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, particularly in women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G4bbb82b7-a53f-42bf-9d14-c1d8ba27e92e"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Exacerbation of Other Conditions </h2>
<p class="First">Estrogen therapy may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ga619b461-abc3-470d-9d63-d41d346e2613"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Laboratory Tests </h2>
<p class="First">Serum follicle stimulating hormone and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gaada22aa-e943-4c95-8f42-030a0f25608a"></a><a name="section-5.18"></a><p></p>
<h2>5.18 Drug-Laboratory Test Interactions </h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</p>
<p>Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> levels (by column or by radioimmunoassay), or T<span class="Sub">3</span> levels by radioimmunoassay. T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.</p>
<p>Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</p>
<p>Increased plasma HDL and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentrations, increased triglyceride levels.</p>
<p>Impaired glucose tolerance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="G504871dc-fe75-4d87-a945-932c17ada06a"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> <span class="Italics">[see <a href="#s2">Boxed Warnin</a>g, Warnings and Precautions (<a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">5.1</a>)]</span>
</li>
<li>Breast Cancer <span class="Italics">[see <a href="#s2">Boxed Warning</a>, Warnings and Precautions, Malignant Neoplasms (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="G035981b2-cc74-422a-93d3-cc69fc8c6bec"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Study Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In a 1-year clinical trial that included 678 postmenopausal women treated with PREMPRO and 351 postmenopausal women treated with PREMPHASE, the following adverse events occurred at a rate ≥ 5 percent, see <a href="#G10d1badf-f829-4ccc-856c-5aff9dd931ab">Table 1</a>.</p>
<a name="G10d1badf-f829-4ccc-856c-5aff9dd931ab"></a><table border="1" frame="border">
<caption><span>TABLE 1: ALL TREATMENT EMERGENT STUDY EVENTS REGARDLESS OF DRUG RELATIONSHIP REPORTED AT A FREQUENCY ≥ 5% </span></caption>
<colgroup>
<col width="152px">
<col width="148px">
<col width="148px">
<col width="156px">
</colgroup>
<thead valign="bottom">
<tr valign="bottom">
<th valign="bottom"> </th>
<th valign="bottom">PREMPRO</th>
<th valign="bottom">PREMPRO</th>
<th valign="bottom">PREMPHASE</th>
</tr>
<tr class="Last" valign="bottom">
<th valign="bottom">Body System</th>
<th valign="bottom">0.625 mg/2.5 mg continuous </th>
<th valign="bottom">0.625 mg/5 mg continuous </th>
<th valign="bottom">0.625 mg/5 mg <br>sequential </th>
</tr>
</thead>
<tbody>
<tr class="First">
<td>     Adverse event </td>
<td align="center">(n = 340) </td>
<td align="center">(n = 338) </td>
<td align="center">(n = 351) </td>
</tr>
<tr>
<td>
<br><span class="Bold">Body As A Whole</span>
</td>
<td align="center" colspan="3"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> </td>
<td align="center">16% </td>
<td align="center">21% </td>
<td align="center">23% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span> </td>
<td align="center">5% </td>
<td align="center">4% </td>
<td align="center">5% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> </td>
<td align="center">6% </td>
<td align="center">8% </td>
<td align="center">10% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> </td>
<td align="center">14% </td>
<td align="center">13% </td>
<td align="center">16% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span> </td>
<td align="center">10% </td>
<td align="center">13% </td>
<td align="center">12% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </td>
<td align="center">36% </td>
<td align="center">28% </td>
<td align="center">37% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </td>
<td align="center">16% </td>
<td align="center">16% </td>
<td align="center">18% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </td>
<td align="center">11% </td>
<td align="center">13% </td>
<td align="center">12% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> </td>
<td align="center">4% </td>
<td align="center">5% </td>
<td align="center">5% </td>
</tr>
<tr>
<td>
<br><span class="Bold">Digestive System</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </td>
<td align="center">6% </td>
<td align="center">6% </td>
<td align="center">5% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> </td>
<td align="center">6% </td>
<td align="center">6% </td>
<td align="center">5% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> </td>
<td align="center">8% </td>
<td align="center">9% </td>
<td align="center">8% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </td>
<td align="center">11% </td>
<td align="center">9% </td>
<td align="center">11% </td>
</tr>
<tr>
<td>
<br><span class="Bold">Metabolic and Nutritional</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> </td>
<td align="center">4% </td>
<td align="center">4% </td>
<td align="center">3% </td>
</tr>
<tr>
<td>
<br><span class="Bold">Musculoskeletal System</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> </td>
<td align="center">9% </td>
<td align="center">7% </td>
<td align="center">9% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> </td>
<td align="center">3% </td>
<td align="center">4% </td>
<td align="center">5% </td>
</tr>
<tr>
<td>
<br><span class="Bold">Nervous System</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </td>
<td align="center">6% </td>
<td align="center">11% </td>
<td align="center">11% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </td>
<td align="center">5% </td>
<td align="center">3% </td>
<td align="center">4% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span> </td>
<td align="center">4% </td>
<td align="center">3% </td>
<td align="center">3% </td>
</tr>
<tr>
<td>
<br><span class="Bold">Respiratory System</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> </td>
<td align="center">11% </td>
<td align="center">11% </td>
<td align="center">13% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> </td>
<td align="center">8% </td>
<td align="center">6% </td>
<td align="center">8% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> </td>
<td align="center">8% </td>
<td align="center">7% </td>
<td align="center">7% </td>
</tr>
<tr>
<td>
<br><span class="Bold">Skin and Appendages</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> </td>
<td align="center">10% </td>
<td align="center">8% </td>
<td align="center">5% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </td>
<td align="center">4% </td>
<td align="center">6% </td>
<td align="center">4% </td>
</tr>
<tr>
<td>
<br><span class="Bold">Urogenital System</span>
</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> </td>
<td align="center">33% </td>
<td align="center">38% </td>
<td align="center">32% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="194088" conceptname="Hypertrophic elongation of cervix">cervix disorder</span> </td>
<td align="center">4% </td>
<td align="center">4% </td>
<td align="center">5% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> </td>
<td align="center">8% </td>
<td align="center">5% </td>
<td align="center">13% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span> </td>
<td align="center">6% </td>
<td align="center">5% </td>
<td align="center">9% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span> </td>
<td align="center">2% </td>
<td align="center">1% </td>
<td align="center">3% </td>
</tr>
<tr class="Last">
<td>   <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> </td>
<td align="center">7% </td>
<td align="center">7% </td>
<td align="center">5% </td>
</tr>
</tbody>
</table>
<p>During the first year of a 2-year clinical trial with postmenopausal women between 40 and 65 years of age (88% Caucasian), 989 postmenopausal women received continuous regimens of PREMPRO, and 332 received placebo tablets. Table 2 summarizes adverse events that occurred at a rate ≥ 5 percent in at least 1 treatment group.</p>
<a name="G8f410cb1-9198-42b5-87f9-4908f761fc0c"></a><table border="1" frame="border">
<caption><span>TABLE 2: PERCENT OF PATIENTS WITH TREATMENT EMERGENT STUDY EVENTS REGARDLESS OF DRUG RELATIONSHIP REPORTED AT A FREQUENCY ≥ 5% DURING STUDY YEAR 1 </span></caption>
<colgroup>
<col width="152px">
<col width="116px">
<col width="116px">
<col width="116px">
<col width="112px">
</colgroup>
<thead valign="bottom">
<tr valign="bottom">
<th valign="bottom">Body System</th>
<th valign="bottom">Prempro<br>0.625 mg/<br>2.5 mg<br>continuous </th>
<th valign="bottom">Prempro<br>0.45 mg/<br>1.5 mg<br>continuous </th>
<th valign="bottom">Prempro<br>0.3 mg/<br>1.5 mg<br>continuous </th>
<th align="center" valign="bottom">Placebo<br>daily </th>
</tr>
<tr class="Last" valign="bottom">
<th valign="bottom">Adverse event</th>
<th align="center" valign="middle">(n = 331)</th>
<th align="center" valign="middle">(n = 331)</th>
<th align="center" valign="middle">(n = 327)</th>
<th align="center" valign="middle">(n = 332)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td>Any adverse event </td>
<td align="center" valign="bottom">92% </td>
<td align="center" valign="bottom">89%</td>
<td align="center" valign="bottom">90%</td>
<td align="center" valign="bottom">85%</td>
</tr>
<tr><td colspan="5">
<br><span class="Bold">Body As A Whole</span>
</td></tr>
<tr>
<td>   abdominal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center" valign="bottom">17% </td>
<td align="center" valign="bottom">16% </td>
<td align="center" valign="bottom">13% </td>
<td align="center" valign="bottom">11% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span> </td>
<td align="center" valign="bottom">10% </td>
<td align="center" valign="bottom">9% </td>
<td align="center" valign="bottom">9% </td>
<td align="center" valign="bottom">9% </td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> </td>
<td align="center">8%</td>
<td align="center">8%</td>
<td align="center">6%</td>
<td align="center">5%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></td>
<td align="center">12%</td>
<td align="center">13%</td>
<td align="center">12%</td>
<td align="center">12%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span></td>
<td align="center">8%</td>
<td align="center">11%</td>
<td align="center">10%</td>
<td align="center">11%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td>
<td align="center">28%</td>
<td align="center">29%</td>
<td align="center">33%</td>
<td align="center">28%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td align="center">21%</td>
<td align="center">19%</td>
<td align="center">18%</td>
<td align="center">22%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center">14%</td>
<td align="center">15%</td>
<td align="center">20%</td>
<td align="center">18%</td>
</tr>
<tr><td colspan="5">
<br><span class="Bold">Digestive System</span>
</td></tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></td>
<td align="center">7%</td>
<td align="center">7%</td>
<td align="center">6%</td>
<td align="center">6%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span></td>
<td align="center">8%</td>
<td align="center">8%</td>
<td align="center">8%</td>
<td align="center">14%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span></td>
<td align="center">7%</td>
<td align="center">8%</td>
<td align="center">5%</td>
<td align="center">3%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td align="center">7%</td>
<td align="center">10%</td>
<td align="center">8%</td>
<td align="center">9%</td>
</tr>
<tr><td colspan="5">
<br><span class="Bold">Musculoskeletal System</span>
</td></tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> </td>
<td align="center">9%</td>
<td align="center">13%</td>
<td align="center">10%</td>
<td align="center">12%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span></td>
<td align="center">7%</td>
<td align="center">5%</td>
<td align="center">4%</td>
<td align="center">2%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> </td>
<td align="center">5%</td>
<td align="center">5%</td>
<td align="center">4%</td>
<td align="center">8%</td>
</tr>
<tr><td colspan="5">
<br><span class="Bold">Nervous System</span>
</td></tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </td>
<td align="center">4%</td>
<td align="center">5%</td>
<td align="center">2%</td>
<td align="center">4%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </td>
<td align="center">11%</td>
<td align="center">5%</td>
<td align="center">8%</td>
<td align="center">7%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </td>
<td align="center">3%</td>
<td align="center">5%</td>
<td align="center">5%</td>
<td align="center">5%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> </td>
<td align="center">6%</td>
<td align="center">7%</td>
<td align="center">6%</td>
<td align="center">10%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> </td>
<td align="center">3%</td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr><td colspan="5">
<br><span class="Bold">Respiratory System</span>
</td></tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span></td>
<td align="center" valign="bottom">8%</td>
<td align="center" valign="bottom">5%</td>
<td align="center" valign="bottom">6%</td>
<td align="center" valign="bottom">4%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> </td>
<td align="center">11%</td>
<td align="center">8%</td>
<td align="center">9%</td>
<td align="center">11%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> </td>
<td align="center">8%</td>
<td align="center">9%</td>
<td align="center">10%</td>
<td align="center">13%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> </td>
<td align="center">8%</td>
<td align="center">8%</td>
<td align="center">10%</td>
<td align="center">7%</td>
</tr>
<tr>
<td>   upper <br>   <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span></td>
<td align="center">10%</td>
<td align="center">9%</td>
<td align="center">11%</td>
<td align="center">11%</td>
</tr>
<tr><td colspan="5">
<br><span class="Bold">Skin and Appendages</span>
</td></tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> </td>
<td align="center">4%</td>
<td align="center">5%</td>
<td align="center">5%</td>
<td align="center">2%</td>
</tr>
<tr><td colspan="5">
<br><span class="Bold">Urogenital System</span>
</td></tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span></td>
<td align="center">5%</td>
<td align="center">3%</td>
<td align="center">2%</td>
<td align="center">&lt;1%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span></td>
<td align="center">26%</td>
<td align="center">21%</td>
<td align="center">13%</td>
<td align="center">9%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span></td>
<td align="center" valign="bottom">5%</td>
<td align="center" valign="bottom">6%</td>
<td align="center" valign="bottom">3%</td>
<td align="center" valign="bottom">&lt;1%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span> </td>
<td align="center" valign="bottom">4%</td>
<td align="center" valign="bottom">5%</td>
<td align="center" valign="bottom">3%</td>
<td align="center" valign="bottom">3%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span></td>
<td align="center" valign="bottom">6%</td>
<td align="center" valign="bottom">4%</td>
<td align="center" valign="bottom">2%</td>
<td align="center" valign="bottom">0%</td>
</tr>
<tr>
<td>   <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal moniliasis</span></td>
<td align="center">8%</td>
<td align="center">7%</td>
<td align="center">4%</td>
<td align="center">2%</td>
</tr>
<tr class="Last">
<td>   <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> </td>
<td align="center">5%</td>
<td align="center">6%</td>
<td align="center">4%</td>
<td align="center">1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G0492b2cf-8980-49cf-9daa-b7df94c7e45c"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been reported with PREMPRO or PREMPHASE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Gf7250055-7c79-4202-9518-436889130f1b"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Italics">Genitourinary System</span></h3>
<p class="First">Abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>/<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, increase in size of uterine leiomyomata, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, changes in cervical secretion, ovarian cancer, <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, endometrial cancer. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G9eb90d98-3929-428e-b286-765d6c4af165"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="Italics">Breasts</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes, breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G472e5486-9b45-4167-8a86-764ca4b1c762"></a><a name="section-6.2.3"></a><p></p>
<h3><span class="Italics">Cardiovascular</span></h3>
<p class="First">Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="442058" conceptname="Superficial thrombophlebitis in pregnancy and the puerperium">superficial thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, increase in blood pressure. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G6d2e9eea-7893-4792-abfd-4da026f6116a"></a><a name="section-6.2.4"></a><p></p>
<h3><span class="Italics">Gastrointestinal</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, changes in appetite, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G499d6e28-ae9d-4eff-b67a-7fef3741bd8f"></a><a name="section-6.2.5"></a><p></p>
<h3><span class="Italics">Skin</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> that may persist when drug is discontinued, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, loss of scalp hair, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G8ca7dd16-31ce-461e-97b2-e9d787ffb50a"></a><a name="section-6.2.6"></a><p></p>
<h3><span class="Italics">Eyes</span></h3>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, intolerance of contact lenses. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G38fe7f65-1e22-4f39-8956-735244d2fb57"></a><a name="section-6.2.7"></a><p></p>
<h3><span class="Italics">Central Nervous System (CNS)</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, mood disturbances, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, growth potentiation of <span class="product-label-link" type="condition" conceptid="376063" conceptname="Benign neoplasm of cerebral meninges">benign meningioma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gf6659120-4913-4cdb-a2dc-07f4464c261e"></a><a name="section-6.2.8"></a><p></p>
<h3><span class="Italics">Miscellaneous</span></h3>
<p class="First">Increase or decrease in weight, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, changes in libido, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, increased triglycerides, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>Additional postmarketing adverse reactions have been reported in patients receiving other forms of hormone therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="G994a5c2a-1bb0-4fef-a081-f55ed8cbf52f"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Data from a single-dose drug-drug interaction study involving conjugated estrogens and medroxyprogesterone acetate indicate that the pharmacokinetic disposition of both drugs is not altered when the drugs are coadministered. No other clinical drug-drug interaction studies have been conducted with CE plus MPA.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="G677fe89f-9743-485e-908e-517f8af25058"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Metabolic Interactions</h2>
<p class="First"><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John's Wort (<span class="Italics">Hypericum perforatum</span>) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4, such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice, may increase plasma concentrations of estrogens and may result in side effects.</p>
<p>Aminoglutethimide administered concomitantly with MPA may significantly depress the bioavailability of MPA.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="G4905eee8-3be0-472c-a611-a3c6ef1e9ba0"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Gc6a38475-cc42-498a-87f4-3e8f36f867c5"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">PREMPRO and PREMPHASE should not be used during pregnancy <span class="Italics">[see Contraindications (<a href="#G272f4123-7baa-4a22-95c5-7195ee6b55bd">4</a>)]</span>. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="G7fd487b1-7d7d-4f97-abe4-ed74b04bfc95"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">PREMPRO and PREMPHASE should not be used during lactation. Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogen and progestin have been identified in the breast milk of mothers receiving these drugs. Caution should be exercised when PREMPRO or PREMPHASE is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Gf131ef1e-fa76-466e-9ca8-3e396ab917f2"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">PREMPRO and PREMPHASE are not indicated in children. Clinical studies have not been conducted in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Gbc11ba00-fb03-4c51-b24f-c68292c02926"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric women involved in clinical studies utilizing PREMPRO or PREMPHASE to determine whether those over 65 years of age differ from younger subjects in their response to PREMPRO or PREMPHASE.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Gb5ea5b79-aef3-421f-a27a-5e251b9d82cb"></a><a name="section-8.4.1"></a><p></p>
<h3><span class="Italics">The Women’s Health Initiative Study</span></h3>
<p class="First">In the Women’s Health Initiative (WHI) estrogen plus progestin substudy (daily conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg), there was a higher relative risk of nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women greater than 65 years of age <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a></span><span class="Italics">)]</span>.</p>
<p>In the WHI estrogen-alone substudy (daily CE [0.625 mg] versus placebo), there was a higher relative risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women greater than 65 years of age <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#Gdd524ac2-4b4e-4283-afba-e98ebf842df0">14.6</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G4e38744a-e0b8-4f7f-bacf-248b7ff51378"></a><a name="section-8.4.2"></a><p></p>
<h3><span class="Italics">The Women’s Health Initiative Memory Study</span></h3>
<p class="First">In the Women’s Health Initiative Memory Study (WHIMS) of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see Clinical Studies (<a href="#Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899">14.7</a>)]</span>.</p>
<p>Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8</span><span class="Italics">[see Clinical Studies (<a href="#G873c3b0f-f415-4089-9963-e7aeae7f435a">14.7</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gb3e30296-6d7e-4648-adee-315b35637203"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The effects of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on PREMPRO or PREMPHASE pharmacokinetics have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G7381f685-d453-4a0c-b285-d5ef1a875a59"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The effects of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on PREMPRO or PREMPHASE pharmacokinetics have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Gb2fe7967-b1d7-43cd-a85f-c07cadb90a15"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of estrogen or estrogen plus progestin may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in women. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists of discontinuation of PREMPRO or PREMPHASE therapy with institution of appropriate symptomatic care.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Gee999cfc-7088-4449-824b-4d3ed5f25e6c"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Premarin (conjugated estrogens tablets, USP) for oral administration contains a mixture obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains as concomitant components, as sodium sulfate conjugates, 17 α-dihydroequilin, 17 α‑estradiol and 17 β-dihydroequilin. </p>
<p>Medroxyprogesterone acetate is a derivative of progesterone. It is a white to off-white, odorless, crystalline powder, stable in air, melting between 200°C and 210°C. It is freely soluble in chloroform, soluble in acetone and in dioxane, sparingly soluble in alcohol and in methanol, slightly soluble in ether, and insoluble in water. The chemical name for MPA is pregn-4-ene-3, 20-dione, 17-(acetyloxy)-6-methyl-, (6α)-. Its molecular formula is C<span class="Sub">24</span>H<span class="Sub">34</span>O<span class="Sub">4</span>, with a molecular weight of 386.53. Its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=prempro-premphase-01.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-10.1"></a><p></p>
<p class="First">PREMPRO 0.3 mg/1.5 mg, 0.45 mg/1.5 mg, and 0.625 mg/2.5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, microcrystalline cellulose, hypromellose, hydroxypropyl cellulose, sucrose, Eudragit NE 30D, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-10.2"></a><p></p>
<p class="First">PREMPRO 0.625 mg/5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, calcium sulfate, carnauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylene glycol, sucrose, povidone, titanium dioxide, FD&amp;C Blue No. 2, and black iron oxide.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Gbee254af-98c0-478a-88be-b763961630c4"></a><a name="section-10.2.1"></a><p></p>
<h3><span class="Bold">PREMPHASE</span></h3>
<p class="First">Each maroon Premarin tablets for oral administration contain 0.625 mg of conjugated estrogens and the following inactive ingredients: calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, titanium dioxide, FD&amp;C Blue No. 2, and FD&amp;C Red No. 40. These tablets comply with USP Dissolution Test 5.</p>
<p>Each light-blue tablet for oral administration contains 0.625 mg of conjugated estrogens, 5 mg of medroxyprogesterone acetate, and the following inactive ingredients: calcium phosphate tribasic, calcium sulfate, carnauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylene glycol, sucrose, povidone, titanium dioxide, FD&amp;C Blue No. 2, and black iron oxide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gf32e5188-e4cf-412b-8e21-f0aa69df98a5"></a><a name="section-10.2.2"></a><p></p>
<h3>PREMPRO</h3>
<a name="G4dca2e1d-92d8-4cb8-b0bb-779dc54bda13"></a><table border="1" frame="border">
<colgroup>
<col width="304px">
<col width="304px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom">Tablet Strength</th>
<th valign="bottom">Tablet Color Contains</th>
</tr></thead>
<tbody>
<tr class="First">
<td>0.3 mg/1.5 mg</td>
<td>Yellow iron oxide and black iron oxide</td>
</tr>
<tr>
<td>0.45 mg/1.5 mg</td>
<td>Yellow iron oxide and black iron oxide</td>
</tr>
<tr>
<td>0.625 mg/2.5 mg</td>
<td>Red iron oxide, yellow iron oxide, and black iron oxide</td>
</tr>
<tr class="Last">
<td>0.625 mg/5 mg</td>
<td>FD&amp;C Blue No. 2 and black iron oxide </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ga7b895f8-f872-40ab-8817-9f25e844bdab"></a><a name="section-10.2.3"></a><p></p>
<h3>PREMPHASE</h3>
<a name="G6e2906fb-26a4-43e5-b0bf-54f85366f10d"></a><table border="1" frame="border">
<colgroup>
<col width="304px">
<col width="304px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom">Tablet Strength</th>
<th valign="bottom">Tablet Color Contains</th>
</tr></thead>
<tbody>
<tr class="First">
<td>0.625 mg</td>
<td>FD&amp;C Blue No. 2 and FD&amp;C Red No. 40 </td>
</tr>
<tr class="Last">
<td>0.625 mg/5 mg</td>
<td>FD&amp;C Blue No. 2 and black iron oxide</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s9"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Gea15006b-90b1-4ceb-9c1a-b6d912d26a34"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. </p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these gonadotropins seen in postmenopausal women.</p>
<p>Parenterally administered medroxyprogesterone acetate (MPA) inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation; although available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA may achieve its beneficial effect on the endometrium in part by decreasing nuclear estrogen receptors and suppression of epithelial DNA synthesis in endometrial tissue. Androgenic and anabolic effects of MPA have been noted, but the drug is apparently devoid of significant estrogenic activity. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Ga7eb0e32-882e-43e1-9e12-23e0f0eb2dca"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Currently, there are no pharmacodynamic data known for PREMPRO or PREMPHASE tablets.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s10"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="G684298a9-d383-459b-bb03-b0dc72fd6176"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Italics">Absorption</span></h3>
<p class="First">PREMPRO and PREMPHASE contain a formulation of medroxyprogesterone acetate (MPA) that is immediately released and conjugated estrogens that are slowly released over several hours. Conjugated estrogens are water-soluble and are well-absorbed from the gastrointestinal tract after release from the drug formulation. MPA is well absorbed from the gastrointestinal tract. <a href="#G602689a4-125a-4ccc-b23f-75365552bbe5">Table 3</a> and <a href="#G7e30deae-de58-43c8-a232-1e315b91dc79">Table 4</a> summarize the mean pharmacokinetic parameters for select unconjugated and conjugated estrogens and medroxyprogesterone acetate following administration of PREMPRO to healthy, postmenopausal women.</p>
<a name="G02c6598e-1a40-4863-8e06-37c9fbd88633"></a><table border="1" frame="border">
<caption><span>TABLE 3: PHARMACOKINETIC PARAMETERS FOR UNCONJUGATED AND CONJUGATED ESTROGENS (CE) AND MEDROXYPROGESTERONE ACETATE (MPA) </span></caption>
<colgroup>
<col width="88px">
<col width="68px">
<col width="36px">
<col width="40px">
<col width="68px">
<col width="64px">
<col width="36px">
<col width="44px">
<col width="68px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom">DRUG </th>
<th align="center" colspan="4" valign="bottom">3 x 0.625 mg CE/2.5 mg MPA<br>Combination Tablets<br>(n = 75)</th>
<th align="center" colspan="4" valign="bottom">2 x 0.625 mg CE/5 mg MPA<br>Combination Tablets<br>(n = 51)</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="9">BA* = Baseline adjusted<p class="First"><span class="Bold">C</span><span class="Sub">max</span> = peak plasma concentration </p>
<p><span class="Bold">t</span><span class="Sub">max</span> = time peak concentration occurs</p>
<p><span class="Bold">t</span><span class="Sub">1/2</span> = apparent terminal-phase disposition half-life (0.693/λ<span class="Sub">z</span>)</p>
<p><span class="Bold">AUC</span> = total area under the concentration-time curve </p>
<p><span class="Sup">a</span>MPA concentrations in plasma samples obtained following administration of 3 x 0.625 mg CE/2.5 mg MPA combination tablets were measured by gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectroscopy/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectroscopy. MPA concentrations in plasma samples from previous studies with 2 x 0.625 mg CE/2.5 mg MPA combination tablets were measured by radioimmunoassay.</p>
</td></tr></tfoot>
<tbody>
<tr class="First"><td align="center" colspan="9"><span class="Bold"><span class="Bold Italics">Unconjugated Estrogens</span></span></td></tr>
<tr>
<td align="center">
<br><span class="Bold">PK Parameter</span>  Arithmetic Mean (%CV) </td>
<td align="center">
<br><span class="Bold">C</span><span class="Sub">max</span><br>(pg/mL)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">max</span><br>(h)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">1/2</span><br>(h)</td>
<td align="center">
<br><span class="Bold">AUC</span><br>(pg•h/mL)</td>
<td align="center">
<br><span class="Bold">C</span><span class="Sub">max</span><br>(pg/mL)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">max</span><br>(h)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">1/2</span><br>(h)</td>
<td align="center">
<br><span class="Bold">AUC</span><br>(pg•h/mL)</td>
</tr>
<tr>
<td>Estrone </td>
<td align="center">163<br>(40)</td>
<td align="center">8.7<br>(58)</td>
<td align="center">35.9<br>(35)</td>
<td align="center">6859<br>(37)</td>
<td align="center">124<br>(43)</td>
<td align="center">10<br>(35)</td>
<td align="center">62.2<br>(137)</td>
<td align="center">6303<br>(40)</td>
</tr>
<tr>
<td>BA* -Estrone</td>
<td align="center">143<br>(45)</td>
<td align="center">8.7<br>(58)</td>
<td align="center">20.7<br>(33)</td>
<td align="center">4042<br>(42)</td>
<td align="center">104<br>(49)</td>
<td align="center">10<br>(35)</td>
<td align="center">26.0<br>(100)</td>
<td align="center">3136<br>(51)</td>
</tr>
<tr>
<td>Equilin </td>
<td align="center">82<br>(45)</td>
<td align="center">7.5<br>(50)</td>
<td align="center">14.3<br>(36)</td>
<td align="center">1729<br>(34)</td>
<td align="center">54<br>(43)</td>
<td align="center">8.9<br>(34)</td>
<td align="center">15.5<br>(53)</td>
<td align="center">1179<br>(56)</td>
</tr>
<tr><td align="center" colspan="9"><span class="Bold"><span class="Bold Italics">Conjugated Estrogens</span></span></td></tr>
<tr>
<td align="center">
<br><span class="Bold">PK Parameter</span>  Arithmetic Mean (%CV) </td>
<td align="center">
<br><span class="Bold">C</span><span class="Sub">max</span><br>(ng/mL)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">max</span><br>(h)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">1/2</span><br>(h)</td>
<td align="center">
<br><span class="Bold">AUC</span><br>(ng•h/mL)</td>
<td align="center">
<br><span class="Bold">C</span><span class="Sub">max</span><br> (ng/mL)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">max</span><br>(h)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">1/2</span><br>(h)</td>
<td align="center">
<br><span class="Bold">AUC</span><br>(ng•h/mL)</td>
</tr>
<tr>
<td>Total Estrone </td>
<td align="center">5.8<br>(45)</td>
<td align="center">7.4<br>(39)</td>
<td align="center">22.8<br>(40)</td>
<td align="center">127<br>(43)</td>
<td align="center">6.3<br>(48) </td>
<td align="center">9.1<br>(29)</td>
<td align="center">23.6<br>(36)</td>
<td align="center">151<br>(42)</td>
</tr>
<tr>
<td>BA* -Total Estrone</td>
<td align="center">5.6<br>(46)</td>
<td align="center">7.4<br>(39)</td>
<td align="center">16.0<br>(36)</td>
<td align="center">107<br>(42)</td>
<td align="center">6.2<br>(48)</td>
<td align="center">9.1<br>(29)</td>
<td align="center">20.6<br>(35)</td>
<td align="center">139<br>(40)</td>
</tr>
<tr>
<td>Total Equilin </td>
<td align="center">4.4<br>(48)</td>
<td align="center">5.7<br>(46)</td>
<td align="center">11.8<br>(36)</td>
<td align="center">68<br>(41)</td>
<td align="center">4.2<br>(52)</td>
<td align="center">7.0<br>(36)</td>
<td align="center">17.2<br>(131)</td>
<td align="center">72<br>(50)</td>
</tr>
<tr><td align="center" colspan="9">
<span class="Bold"><span class="Bold Italics">Medroxyprogesterone Acetate</span></span><span class="Sup">a</span>
</td></tr>
<tr>
<td align="center">
<br><span class="Bold">PK Parameter</span><br>Arithmetic Mean (%CV) </td>
<td align="center">
<br><span class="Bold">C</span><span class="Sub">max</span><br>(ng/mL)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">max</span><br>(h)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">1/2</span><br>(h)</td>
<td align="center">
<br><span class="Bold">AUC</span><br>(ng•h/mL)</td>
<td align="center">
<br><span class="Bold">C</span><span class="Sub">max</span><br>(ng/mL)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">max</span><br> (h)</td>
<td align="center">
<br><span class="Bold">t</span><span class="Sub">1/2</span><br>(h)</td>
<td align="center">
<br><span class="Bold">AUC</span><br>(ng•h/mL)</td>
</tr>
<tr class="Last">
<td>MPA</td>
<td align="center">0.9<br>(67)</td>
<td align="center">2.0<br>(46)</td>
<td align="center">28.1<br>(25)</td>
<td align="center">6.0<br>(60)</td>
<td align="center">4.8<br>(31)</td>
<td align="center">2.4<br>(50)</td>
<td align="center">46.3<br>(39)</td>
<td align="center">102<br>(28)</td>
</tr>
</tbody>
</table>
<a name="G39d4b1d0-67da-482c-9cd5-0925aeddd54b"></a><table border="1" frame="border">
<caption><span>TABLE 4. PHARMACOKINETIC PARAMETERS FOR UNCONJUGATED AND CONJUGATED ESTROGENS (CE) AND MEDROXYPROGESTERONE ACETATE (MPA)</span></caption>
<colgroup>
<col width="144px">
<col width="100px">
<col width="124px">
<col width="124px">
<col width="124px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom">DRUG </th>
<th align="center" colspan="4" valign="bottom">4 x 0.45 mg CE/1.5 mg MPA Combination<br>(n = 65)</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="5">BA* = Baseline adjusted<p class="First"><span class="Bold">C</span><span class="Sub">max</span> = peak plasma concentration</p>
<p><span class="Bold">t</span><span class="Sub">max</span> = time peak concentration occurs </p>
<p><span class="Bold">t</span><span class="Sub">1/2</span> = apparent terminal-phase disposition half-life (0.693/λ<span class="Sub">z</span>)</p>
<p><span class="Bold">AUC</span> = total area under the concentration-time curve </p>
<p><span class="Sup">a</span>MPA concentrations in plasma samples obtained following administration of 4 x 0.45 mg CE/1.5 mg MPA combination tablets were measured by gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectroscopy/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectroscopy.</p>
</td></tr></tfoot>
<tbody>
<tr class="First"><td align="center" colspan="5"><span class="Bold"><span class="Bold Italics">Unconjugated Estrogens</span></span></td></tr>
<tr>
<td>
<span class="Bold">PK Parameter</span><br>   Arithmetic Mean (%CV)</td>
<td align="center">
<span class="Bold">C</span><span class="Sub">max</span><br> (pg/mL)</td>
<td align="center">
<span class="Bold">t</span><span class="Sub">max</span><br> (h)</td>
<td align="center">
<span class="Bold">t</span><span class="Sub">1/2</span><br> (h)</td>
<td align="center">
<span class="Bold">AUC</span><br>(pg•h/mL)</td>
</tr>
<tr>
<td>Estrone </td>
<td align="center">149<br>     (35)</td>
<td align="center">8.9<br>     (35) </td>
<td align="center">37.5<br>     (35)</td>
<td align="center">6641<br>     (39)</td>
</tr>
<tr>
<td>BA* -Estrone</td>
<td align="center">130<br>     (40)</td>
<td align="center">8.9<br>     (35) </td>
<td align="center">21.2<br>     (35)</td>
<td align="center">3799<br>     (47)</td>
</tr>
<tr>
<td>Equilin </td>
<td align="center">83<br>     (38)</td>
<td align="center">8.3<br>     (48)</td>
<td align="center">15.9<br>     (44)</td>
<td align="center">1889<br>     (40)</td>
</tr>
<tr><td align="center" colspan="5"><span class="Bold"><span class="Bold Italics">Conjugated Estrogens</span></span></td></tr>
<tr>
<td>
<span class="Bold">PK Parameter</span><br>   Arithmetic Mean (%CV)</td>
<td align="center">
<span class="Bold">C</span><span class="Sub">max</span><br>     (ng/mL)</td>
<td align="center">
<span class="Bold">t</span><span class="Sub">max</span><br>     (h)</td>
<td align="center">
<span class="Bold">t</span><span class="Sub">1/2</span><br>     (h)</td>
<td align="center">
<span class="Bold">AUC</span><br>     (ng•h/mL)</td>
</tr>
<tr>
<td>Total Estrone </td>
<td align="center">5.4<br>     (49)</td>
<td align="center">7.9<br>     (48)</td>
<td align="center">22.4<br>     (53)</td>
<td align="center">119<br>     (48)</td>
</tr>
<tr>
<td>BA* -Total Estrone</td>
<td align="center">5.2<br>     (48)</td>
<td align="center">7.9<br>     (48)</td>
<td align="center">15.1<br>     (29)</td>
<td align="center">100<br>     (47)</td>
</tr>
<tr>
<td>Total Equilin </td>
<td align="center">4.3<br>     (42)</td>
<td align="center">6.5<br>     (45)</td>
<td align="center">11.6<br>     (31)</td>
<td align="center">74<br>     (48)</td>
</tr>
<tr><td align="center" colspan="5">
<span class="Bold"><span class="Bold Italics">Medroxyprogesterone Acetate</span></span><span class="Sup">a</span>
</td></tr>
<tr>
<td valign="bottom">
<span class="Bold">PK Parameter</span><br>   Arithmetic Mean (%CV) </td>
<td align="center">
<span class="Bold">C</span><span class="Sub">max</span><br>     (ng/mL)</td>
<td align="center">
<span class="Bold">t</span><span class="Sub">max</span><br>     (h)</td>
<td align="center">
<span class="Bold">t</span><span class="Sub">1/2</span><br>     (h)</td>
<td align="center">
<span class="Bold">AUC</span><br>     (ng•h/mL)</td>
</tr>
<tr class="Last">
<td>MPA</td>
<td align="center">0.7<br>   (66)</td>
<td align="center">2.0<br>   (52) </td>
<td align="center">26.2<br>   (35) </td>
<td align="center">5.0<br>   (61) </td>
</tr>
</tbody>
</table>
<p>Food-Effect: Single dose studies in healthy, postmenopausal women were conducted to investigate any potential drug interaction when PREMPRO or PREMPHASE is administered with a high-fat breakfast. Administration with food decreased the C<span class="Sub">max</span> of total estrone by 18 to 34 percent and increased total equilin C<span class="Sub">max</span> by 38 percent compared to the fasting state, with no other effect on the rate or extent of absorption of other conjugated or unconjugated estrogens. Administration with food approximately doubles MPA C<span class="Sub">max</span> and increases MPA AUC by approximately 20 to 30 percent. </p>
<p>Dose Proportionality: The C<span class="Sub">max</span> and AUC values for MPA observed in two separate pharmacokinetic studies conducted with 2 PREMPRO 0.625 mg/2.5 mg or 2 PREMPRO or PREMPHASE 0.625 mg/5 mg tablets exhibited nonlinear dose proportionality; doubling the MPA dose from 2 x 2.5 to 2 x 5 mg increased the mean C<span class="Sub">max</span> and AUC by 3.2- and 2.8-fold, respectively. </p>
<p>The dose proportionality of estrogens and MPA was assessed by combining pharmacokinetic data across another two studies totaling 61 healthy, postmenopausal women. Single conjugated estrogens doses of 2 x 0.3 mg, 2 x 0.45 mg, or 2 x 0.625 mg were administered either alone or in combination with MPA doses of 2 x 1.5 mg or 2 x 2.5 mg. Most of the estrogen components demonstrated dose proportionality; however, several estrogen components did not. MPA pharmacokinetic parameters increased in a dose-proportional manner. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Italics">Distribution</span></h3>
<p class="First">The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to sex hormone‑binding globulin (SHBG) and albumin. MPA is approximately 90 percent bound to plasma proteins, but does not bind to SHBG. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Italics">Metabolism</span></h3>
<p class="First">Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Metabolism and elimination of MPA occur primarily in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Italics">Excretion</span></h3>
<p class="First">Estradiol, estrone, and estriol are excreted in the urine, along with glucuronide and sulfate conjugates. Most metabolites of MPA are excreted as glucuronide conjugates, with only minor amounts excreted as sulfates. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Italics">Specific Populations</span></h3>
<p class="First">No pharmacokinetic studies were conducted in specific populations, including patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Ga5663a09-fc62-4eba-8a6c-0044fd483304"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Gb908a0db-831a-4800-b3e4-8b908f930c4c"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breasts, uterus, cervix, vagina, testis, and liver. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="G79dbe231-f81b-4f90-b5c9-3850131ffa9b"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="G86e19cb6-6b09-4522-88c3-565079afa4ff"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Effects on Vasomotor Symptoms</h2>
<p class="First">In the first year of the Health and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span>, Progestin and Estrogen (HOPE) Study, a total of 2,805 postmenopausal women (average age 53.3 ± 4.9 years) were randomly assigned to one of eight treatment groups of either placebo or conjugated estrogens, with or without medroxyprogesterone acetate. Efficacy for vasomotor symptoms was assessed during the first 12 weeks of treatment in a subset of symptomatic women (n = 241) who had at least seven moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> daily, or at least 50 moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> during the week before randomization. With PREMPRO 0.625 mg/2.5 mg, 0.45 mg/1.5 mg, and 0.3 mg/1.5 mg, the relief of both the frequency and severity of moderate-to-severe vasomotor symptoms was shown to be statistically improved compared to placebo at weeks 4 and 12. <a href="#Gffa3d147-4388-4ab6-9c86-c042cb0b324c">Table 5</a> shows the adjusted mean number of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> in the PREMPRO 0.625 mg/2.5 mg, 0.45 mg/1.5 mg, 0.3 mg/1.5 mg, and placebo groups during the initial 12-week period.</p>
<a name="Gffa3d147-4388-4ab6-9c86-c042cb0b324c"></a><table border="1" frame="border">
<caption><span>TABLE 5: SUMMARY TABULATION OF THE NUMBER OF <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">HOT FLUSHES</span> PER DAY – MEAN VALUES AND COMPARISONS BETWEEN THE ACTIVE TREATMENT GROUPS AND THE PLACEBO GROUP – PATIENTS WITH AT LEAST 7 MODERATE TO SEVERE FLUSHES PER DAY OR AT LEAST 50 PER WEEK AT BASELINE, LAST OBSERVATION CARRIED FORWARD (LOCF) </span></caption>
<colgroup>
<col width="220px">
<col width="172px">
<col width="68px">
<col width="60px">
<col width="68px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom">Treatment<span class="Sup">a</span><br>(No. of Patients) </th>
<th colspan="4" valign="bottom">-------------------No. of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span>/Day-----------------</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span> Identified by dosage (mg) of Premarin/MPA or placebo.<p class="First"><span class="Sup">b</span> There were no statistically significant differences between the 0.625 mg/2.5 mg, 0.45 mg/1.5 mg, and 0.3 mg/1.5 mg groups at any time period.</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="bottom">Time Period<br>(week) </td>
<td align="center" valign="middle">Baseline<br>Mean ± SD </td>
<td align="center" valign="middle">Observed<br>Mean ± SD </td>
<td align="center" valign="middle">Mean<br>Change ± SD</td>
<td align="center" valign="middle">p-Values<br>vs. Placebo<span class="Sup">b</span>
</td>
</tr>
<tr>
<td align="center" valign="middle">0.625 mg/2.5 mg<br>(n = 34) </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">11.98 ± 3.54 </td>
<td align="center">3.19 ± 3.74</td>
<td align="center">-8.78 ± 4.72</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="center" valign="middle">12</td>
<td align="center">11.98 ± 3.54</td>
<td align="center">1.16 ± 2.22</td>
<td align="center">-10.82 ± 4.61</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="center" valign="middle">0.45 mg/1.5 mg<br>(n = 29)</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="center" valign="middle">4</td>
<td align="center">12.61 ± 4.29</td>
<td align="center">3.64 ± 3.61</td>
<td align="center">-8.98 ± 4.74</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="center" valign="middle">12</td>
<td align="center">12.61 ± 4.29</td>
<td align="center">1.69 ± 3.36</td>
<td align="center">-10.92 ± 4.63</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="center" valign="middle">0.3 mg/1.5 mg<br>(n = 33)</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="center" valign="middle">4</td>
<td align="center">11.30 ± 3.13</td>
<td align="center">3.70 ± 3.29</td>
<td align="center">-7.60 ± 4.71</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="center" valign="middle">12</td>
<td align="center">11.30 ± 3.13</td>
<td align="center">1.31 ± 2.82</td>
<td align="center">-10.00 ± 4.60</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="center" valign="middle">Placebo<br>(n = 28)</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td align="center" valign="middle">4</td>
<td align="center">11.69 ± 3.87</td>
<td align="center">7.89 ± 5.28</td>
<td align="center">-3.80 ± 4.71</td>
<td align="center">-</td>
</tr>
<tr class="Last">
<td align="center" valign="middle">12</td>
<td align="center">11.69 ± 3.87</td>
<td align="center">5.71 ± 5.22</td>
<td align="center">-5.98 ± 4.60</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gc81464d2-4386-4bee-9b25-9c08b009585c"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Effects on Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span></h2>
<p class="First">Results of vaginal maturation indexes at cycles 6 and 13 showed that the differences from placebo were statistically significant (p &lt; 0.001) for all treatment groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G5afd9950-4c50-4a64-940c-56420b5f448e"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Effects on the Endometrium</h2>
<p class="First">In a 1-year clinical trial of 1,376 women (average age 54 ± 4.6 years) randomized to PREMPRO 0.625 mg/2.5 mg (n = 340), PREMPRO 0.625 mg/5 mg (n = 338), PREMPHASE 0.625 mg/5 mg (n = 351), or Premarin 0.625 mg alone (n = 347), results of evaluable biopsies at 12 months (n = 279, 274, 277, and 283, respectively) showed a reduced risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> in the two PREMPRO treatment groups (less than 1 percent) and in the PREMPHASE treatment group (less than 1 percent; 1 percent when focal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was included) compared to the Premarin group (8 percent; 20 percent when focal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was included), see <a href="#t6">Table 6</a>. </p>
<a name="Ge87d326a-cbd5-43a2-9c08-d4740f0f428e"></a><table border="1" frame="border">
<caption><span>TABLE 6: INCIDENCE OF <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">ENDOMETRIAL HYPERPLASIA</span> AFTER ONE YEAR OF TREATMENT</span></caption>
<colgroup>
<col width="284px">
<col width="80px">
<col width="76px">
<col width="64px">
<col width="68px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom"> </th>
<th colspan="4" valign="bottom">--------------------------Groups-------------------------</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="5">* Significant (p &lt; 0.001) in comparison with Premarin (0.625 mg) alone.</td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="bottom"> </td>
<td align="center" valign="middle">PREMPRO<br><br>0.625 mg/<br>2.5 mg</td>
<td align="center">PREMPRO<br><br>0.625 mg/<br>5 mg</td>
<td align="center" valign="middle">PREMPHASE<br><br>0.625 mg/<br>5 mg </td>
<td align="center">Premarin<br><br>0.625 mg</td>
</tr>
<tr>
<td>Total number of patients<br>
</td>
<td align="center">340</td>
<td align="center">338</td>
<td align="center">351</td>
<td align="center">347</td>
</tr>
<tr>
<td>Number of patients with evaluable biopsies </td>
<td align="center">279</td>
<td align="center">274</td>
<td align="center">277</td>
<td align="center">283</td>
</tr>
<tr>
<td>No. (%) of patients with biopsies:</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>• All focal and non-focal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="center">2 (&lt;1)*</td>
<td align="center">0 (0)*</td>
<td align="center">3 (1)*</td>
<td align="center">57 (20)</td>
</tr>
<tr class="Last">
<td>• Excluding focal cystic <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="center">2 (&lt;1)*</td>
<td align="center">0 (0)*</td>
<td align="center">1 (&lt;1)*</td>
<td align="center">25 (8)</td>
</tr>
</tbody>
</table>
<p>In the first year of the Health and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span>, Progestin and Estrogen (HOPE) Study, 2,001 women (average age 53.3 ± 4.9 years), of whom 88 percent were Caucasian, were treated with either Premarin 0.625 mg alone (n = 348), Premarin 0.45 mg alone (n = 338), Premarin 0.3 mg alone (n = 326) or PREMPRO 0.625 mg/2.5 mg (n = 331), PREMPRO 0.45 mg/1.5 mg (n = 331) or PREMPRO 0.3 mg/1.5 mg (n = 327). Results of evaluable endometrial biopsies at 12 months showed a reduced risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> or cancer in the PREMPRO treatment groups compared with the corresponding Premarin alone treatment groups, except for the PREMPRO 0.3 mg/1.5 mg and Premarin 0.3 mg alone groups, in each of which there was only 1 case, see <a href="#t7">Table 7</a>.</p>
<p>No <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> or cancer was noted in those patients treated with the continuous combined regimens who continued for a second year in the <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and metabolic substudy of the HOPE study, see <a href="#t8">Table 8</a>.</p>
<a name="G431240e3-15ce-44b9-8fff-7fe0edc3b64d"></a><table border="1" frame="border">
<caption><span>TABLE 7: INCIDENCE OF <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">ENDOMETRIAL HYPERPLASIA</span>/CANCER<span class="Sup">a</span> AFTER ONE YEAR OF TREATMENT<span class="Sup">b</span></span></caption>
<colgroup>
<col width="196px">
<col width="68px">
<col width="64px">
<col width="64px">
<col width="68px">
<col width="64px">
<col width="68px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom"> </th>
<th colspan="6" valign="bottom">-----------------------------------Groups---------------------------------</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="7">
<span class="Sup">a</span> All cases of <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>/cancer were <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, except for 1 patient in the Premarin 0.3 mg group diagnosed with endometrial cancer based on endometrial biopsy and 1 patient in the Premarin/MPA 0.45 mg/1.5 mg group diagnosed with endometrial cancer based on endometrial biopsy.<p class="First"><span class="Sup">b</span> Two (2) primary pathologists evaluated each endometrial biopsy. Where there was lack of agreement on the presence or absence of <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>/cancer between the two, a third pathologist adjudicated (consensus).</p>
<p><span class="Sup">c</span> For an endometrial biopsy to be counted as consensus <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> or cancer, at least 2 pathologists had to agree on the diagnosis.</p>
<p><span class="Sup">d</span> Significant (p &lt; 0.05) in comparison with corresponding dose of Premarin alone.</p>
<p><span class="Sup">e</span> Non-significant in comparison with corresponding dose of Premarin alone.</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="bottom">Patient</td>
<td align="center" valign="middle">Prempro<br>0.625 mg/<br>2.5 mg</td>
<td align="center">Premarin<br>0.625 mg</td>
<td align="center" valign="middle">Prempro<br>0.45 mg/<br>1.5 mg</td>
<td align="center">Premarin<br>0.45 mg</td>
<td align="center">Prempro<br>0.3 mg/<br>1.5 mg</td>
<td align="center">Premarin 0.3 mg</td>
</tr>
<tr>
<td>Total number of patients<br>
</td>
<td align="center">331</td>
<td align="center">348</td>
<td align="center">331</td>
<td align="center">338</td>
<td align="center">327</td>
<td align="center">326</td>
</tr>
<tr>
<td>Number of patients with evaluable biopsies </td>
<td align="center">278</td>
<td align="center">249</td>
<td align="center">272</td>
<td align="center">279</td>
<td align="center">271</td>
<td align="center">269</td>
</tr>
<tr>
<td>No. (%) of patients with biopsies:</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr class="Last">
<td>• <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">Hyperplasia</span>/cancer<span class="Sup">a</span><br>(consensus<span class="Sup">c</span>)</td>
<td align="center">0 (0)<span class="Sup">d</span>
</td>
<td align="center">20 (8)</td>
<td align="center">1 (&lt;1)<span class="Sup">a,d</span>
</td>
<td align="center">9 (3)</td>
<td align="center">1 (&lt;1)<span class="Sup">e</span>
</td>
<td align="center">1 (&lt;1)<span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
<a name="Gda4b06d1-2947-444a-b054-f70c79177ae9"></a><table border="1" frame="border">
<caption><span>TABLE 8: <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">OSTEOPOROSIS</span> AND METABOLIC SUBSTUDY, INCIDENCE OF <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">ENDOMETRIAL HYPERPLASIA</span>/CANCER<span class="Sup">a</span> AFTER TWO YEARS OF TREATMENT<span class="Sup">b</span></span></caption>
<colgroup>
<col width="196px">
<col width="68px">
<col width="64px">
<col width="64px">
<col width="68px">
<col width="64px">
<col width="68px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom"> </th>
<th colspan="6" valign="bottom">-------------------------------Groups------------------------------</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="7">
<span class="Sup">a</span> All cases of <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>/cancer were <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> in patients who continued for a second year in the <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and metabolic substudy of the HOPE study.<p class="First"><span class="Sup">b</span> Two (2) primary pathologists evaluated each endometrial biopsy. Where there was lack of agreement on the presence or absence of <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>/cancer between the two, a third pathologist adjudicated (consensus).</p>
<p><span class="Sup">c</span> For an endometrial biopsy to be counted as consensus <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> or cancer, at least 2 pathologists had to agree on the diagnosis.</p>
<p><span class="Sup">d</span> Significant (p &lt; 0.05) in comparison with corresponding dose of Premarin alone.</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="bottom">Patient</td>
<td align="center" valign="middle">Prempro<br>0.625 mg/<br>2.5 mg</td>
<td align="center">Premarin<br>0.625 mg</td>
<td align="center" valign="middle">Prempro<br>0.45 mg/<br>1.5 mg</td>
<td align="center">Premarin<br>0.45 mg</td>
<td align="center">Prempro<br>0.3 mg/<br>1.5 mg</td>
<td align="center">Premarin 0.3 mg</td>
</tr>
<tr>
<td>Total number of patients<br>
</td>
<td align="center">75</td>
<td align="center">65</td>
<td align="center">75</td>
<td align="center">74</td>
<td align="center">79</td>
<td align="center">73</td>
</tr>
<tr>
<td>Number of patients with evaluable biopsies </td>
<td align="center">62</td>
<td align="center">55</td>
<td align="center">69</td>
<td align="center">67</td>
<td align="center">75</td>
<td align="center">63</td>
</tr>
<tr>
<td>No. (%) of patients with biopsies:</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr class="Last">
<td>• <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">Hyperplasia</span>/cancer<span class="Sup">a</span><br>(consensus<span class="Sup">c</span>)</td>
<td align="center">0 (0)<span class="Sup">d</span>
</td>
<td align="center">15 (27)</td>
<td align="center">0 (0)<span class="Sup">d</span>
</td>
<td align="center">10 (15)</td>
<td align="center">0 (0)<span class="Sup">d</span>
</td>
<td align="center">2 (3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G62dfb9c0-44be-4e25-a02d-2291db378dcb"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting</h2>
<p class="First">The effects of PREMPRO on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> or spotting, as recorded on daily diary cards, were evaluated in 2 clinical trials. Results are shown in <a href="#Ge26a1498-abc6-4355-a199-6030b3807275">Figures 1</a> and <a href="#G77a6472a-ae04-4de5-b20f-69842a0eeead">2</a>. </p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=prempro-premphase-02.jpg"></div>
<p><span class="Bold">FIGURE 1. PATIENTS WITH CUMULATIVE <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">AMENORRHEA</span> OVER TIME PERCENTAGES OF WOMEN WITH NO <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> OR SPOTTING AT A GIVEN CYCLE THROUGH CYCLE 13 INTENT-TO-TREAT POPULATION, LOCF</span></p>
<p>Note: The percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown. If data were missing, the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> value from the last reported day was carried forward (LOCF). </p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=prempro-premphase-03.jpg"></div>
<p><span class="Bold">FIGURE 2. PATIENTS WITH CUMULATIVE <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">AMENORRHEA</span> OVER TIME PERCENTAGES OF WOMEN WITH NO <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> OR SPOTTING AT A GIVEN CYCLE THROUGH CYCLE 13 INTENT-TO-TREAT POPULATION, LOCF</span></p>
<p>Note: The percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown. If data were missing, the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> value from the last reported day was carried forward (LOCF). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ge74f86e8-4c50-42ac-b4cc-a3ac2085261c"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Effects on Bone Mineral Density</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="G4993efca-3189-4901-8790-b9d5da719cd1"></a><a name="section-13.5.1"></a><p></p>
<h3><span class="Italics">Health and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span>, Progestin and Estrogen (HOPE) Study</span></h3>
<p class="First">The HOPE study was a double-blind, randomized, placebo/active-drug-controlled, multicenter study of healthy postmenopausal women with an intact uterus. Subjects (mean age 53.3 ± 4.9 years) were 2.3 ± 0.9 years on average since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> and took one 600 mg tablet of elemental calcium (Caltrate™) daily. Subjects were not given Vitamin D supplements. They were treated with PREMPRO 0.625 mg/2.5 mg, 0.45 mg/1.5 mg or 0.3 mg/1.5 mg, comparable doses of Premarin alone, or placebo. Prevention of bone loss was assessed by measurement of bone mineral density (BMD), primarily at the anteroposterior lumbar spine (L<span class="Sub">2</span> to L<span class="Sub">4</span>). Secondarily, BMD measurements of the total body, femoral neck, and trochanter were also analyzed. Serum osteocalcin, urinary calcium, and N-telopeptide were used as bone turnover markers (BTM) at cycles 6, 13, 19, and 26. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gee2cc9ea-d140-40a5-be87-5c91034004eb"></a><a name="section-13.5.2"></a><p></p>
<h3><span class="Italics">Intent-to-treat subjects</span></h3>
<p class="First">All active treatment groups showed significant differences from placebo in each of the four BMD endpoints. These significant differences were seen at cycles 6, 13, 19, and 26. </p>
<p>The percent changes from baseline to final evaluation are shown in <a href="#Gd8348b59-49ca-4e53-9f09-7333c946790e">Table 9</a>. </p>
<a name="Gd8348b59-49ca-4e53-9f09-7333c946790e"></a><table border="1" frame="border">
<caption><span>TABLE 9: PERCENT CHANGE IN BONE MINERAL DENSITY: COMPARISON BETWEEN ACTIVE AND PLACEBO GROUPS IN THE INTENT-TO-TREAT POPULATION, LOCF</span></caption>
<colgroup>
<col width="156px">
<col width="128px">
<col width="116px">
<col width="116px">
<col width="100px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom">Region Evaluated Treatment Group<span class="Sup">a</span>
</th>
<th valign="bottom">No. of Subjects</th>
<th valign="bottom">Baseline (g/cm<span class="Sup">2</span>)<br>Mean ± SD</th>
<th valign="bottom">Change from Baseline (%)<br>Adjusted<br>Mean ± SE</th>
<th valign="bottom">p-Value<br>vs.<br>Placebo</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span> Identified by dosage (mg/mg) of Premarin/MPA or placebo.</td></tr></tfoot>
<tbody>
<tr class="First">
<td>L<span class="Sub">2</span> to L<span class="Sub">4</span> BMD</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   0.625/2.5</td>
<td align="center">81</td>
<td align="center">1.14 ± 0.16</td>
<td align="center">3.28 ± 0.37</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   0.45/1.5</td>
<td align="center">89</td>
<td align="center">1.16 ± 0.14</td>
<td align="center">2.18 ± 0.35</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   0.3/1.5</td>
<td align="center">90</td>
<td align="center">1.14 ± 0.15</td>
<td align="center">1.71 ± 0.35</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   Placebo</td>
<td align="center">85</td>
<td align="center">1.14 ± 0.14</td>
<td align="center">-2.45 ± 0.36</td>
<td align="center"> </td>
</tr>
<tr>
<td>Total body BMD</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   0.625/2.5</td>
<td align="center">81</td>
<td align="center">1.14 ± 0.08</td>
<td align="center">0.87 ± 0.17</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   0.45/1.5</td>
<td align="center">89</td>
<td align="center">1.14 ± 0.07</td>
<td align="center">0.59 ± 0.17</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   0.3/1.5</td>
<td align="center">91</td>
<td align="center">1.13 ± 0.08</td>
<td align="center">0.60 ± 0.16</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   Placebo</td>
<td align="center">85</td>
<td align="center">1.13 ± 0.08</td>
<td align="center">-1.50 ± 0.17</td>
<td align="center"> </td>
</tr>
<tr>
<td>Femoral neck BMD</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   0.625/2.5</td>
<td align="center">81</td>
<td align="center">0.89 ± 0.14</td>
<td align="center">1.62 ± 0.46</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   0.45/1.5</td>
<td align="center">89</td>
<td align="center">0.89 ± 0.12</td>
<td align="center">1.48 ± 0.44</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   0.3/1.5</td>
<td align="center">91</td>
<td align="center">0.86 ± 0.11</td>
<td align="center">1.31 ± 0.43</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td>   Placebo</td>
<td align="center">85</td>
<td align="center">0.88 ± 0.14</td>
<td align="center">-1.72 ± 0.45</td>
<td align="center"> </td>
</tr>
<tr>
<td>Femoral trochanter BMD</td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
<td align="center"> </td>
</tr>
<tr>
<td>   0.625/2.5</td>
<td align="center">81</td>
<td align="center">0.77 ± 0.14</td>
<td align="center">3.35 ± 0.59</td>
<td align="center">0.002</td>
</tr>
<tr>
<td>   0.45/1.5</td>
<td align="center">89</td>
<td align="center">0.76 ± 0.12</td>
<td align="center">2.84 ± 0.57</td>
<td align="center">0.011</td>
</tr>
<tr>
<td>   0.3/1.5</td>
<td align="center">91</td>
<td align="center">0.76 ± 0.12</td>
<td align="center">3.93 ± 0.56</td>
<td align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td>   Placebo</td>
<td align="center">85</td>
<td align="center">0.75 ± 0.12</td>
<td align="center">0.81 ± 0.58</td>
<td align="center"> </td>
</tr>
</tbody>
</table>
<p>Figure 3 shows the cumulative percentage of subjects with percent changes from baseline in spine BMD equal to or greater than the percent change shown on the x-axis. </p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=prempro-premphase-04.jpg"></div>
<p><span class="Bold">FIGURE 3. CUMULATIVE PERCENT OF SUBJECTS WITH CHANGES FROM BASELINE IN SPINE BMD OF GIVEN MAGNITUDE OR GREATER IN PREMARIN/MPA AND PLACEBO GROUPS</span></p>
<p>The mean percent changes from baseline in L<span class="Sub">2</span> to L<span class="Sub">4</span> BMD for women who completed the bone density study are shown with standard error bars by treatment group in <a href="#Gce0c21a8-d654-4ea9-856d-20110ab62180">Figure 4</a>. Significant differences between each of the PREMPRO dosage groups and placebo were found at cycles 6, 13, 19, and 26. </p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=prempro-premphase-05.jpg"></div>
<p><span class="Bold">FIGURE 4. ADJUSTED MEAN (SE) PERCENT CHANGE FROM BASELINE AT EACH CYCLE IN SPINE BMD: SUBJECTS COMPLETING IN PREMARIN/MPA GROUPS AND PLACEBO</span></p>
<p>The bone turnover markers, serum osteocalcin and urinary N-telopeptide, significantly decreased (p &lt; 0.001) in all active-treatment groups at cycles 6, 13, 19, and 26 compared with the placebo group. Larger mean decreases from baseline were seen with the active groups than with the placebo group. Significant differences from placebo were seen less frequently in urine calcium; only with PREMPRO 0.625 mg/2.5 mg and 0.45 mg/1.5 mg were there significantly larger mean decreases than with placebo at 3 or more of the 4 time points. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gdd524ac2-4b4e-4283-afba-e98ebf842df0"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Women's Health Initiative Studies</h2>
<p class="First">The Women's Health Initiative (WHI) enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease [(CHD) defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>], with invasive breast cancer as the primary adverse outcome. A “global index? included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes. These substudies did not evaluate the effects of CE plus MPA or CE on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="G6a91e3bd-fada-4769-b673-db51a6a79391"></a><a name="section-13.6.1"></a><p></p>
<h3><span class="Italics">WHI Estrogen Plus Progestin Substudy</span></h3>
<p class="First">The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the “global index.? The absolute excess risk of events included in the “global index? was 19 per 10,000 women-years.</p>
<p>For those outcomes included in the WHI “global index? that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.</p>
<p>Results of the estrogen plus progestin substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 10. These results reflect centrally adjudicated data after an average follow-up of 5.6 years. </p>
<a name="G3afc5cc2-6050-4503-8c08-02bdc5dee765"></a><table border="1" frame="border">
<caption><span>TABLE 10: Relative and Absolute Risk Seen In The Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years<span class="Sup">a,b</span></span></caption>
<colgroup>
<col width="220px">
<col width="180px">
<col width="105px">
<col width="105px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom"> </th>
<th valign="bottom">Relative Risk <br>CE/MPA vs. Placebo<br>(95% nCI<span class="Sup">c</span>) </th>
<th valign="bottom">CE/MPA<br>n = 8,506 </th>
<th valign="bottom">Placebo<br>n = 8,102 </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">a </span>Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.<p class="First"><span class="Sup">b</span> Results are based on centrally adjudicated data. </p>
<p><span class="Sup">c</span> Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</p>
<p><span class="Sup">d</span> Not included in “global index.?</p>
<p><span class="Sup">e</span> Includes metastatic and non-metastatic breast cancer, with the exception of <span class="Italics">in situ</span> breast cancer. </p>
<p><span class="Sup">f</span> All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite/probable CHD, PE or cerebrovascular disease.</p>
<p><span class="Sup">g</span> A subset of the events was combined in a “global index? defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes. </p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td>Event</td>
<td> </td>
<td align="center" colspan="2" valign="middle">Absolute Risk per 10,000 <br>Women-Years </td>
</tr>
<tr>
<td>CHD events </td>
<td align="center">1.23 (0.99–1.53)</td>
<td align="center">41</td>
<td align="center">34</td>
</tr>
<tr>
<td>
<span class="Italics">   Non-fatal MI</span><span class="Sup">c</span>
</td>
<td align="center"><span class="Italics">1.28 (1.00–1.63) </span></td>
<td align="center"><span class="Italics">31</span></td>
<td align="center"><span class="Italics">25</span></td>
</tr>
<tr>
<td><span class="Italics">   CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span></td>
<td align="center"><span class="Italics">1.10 (0.70–1.75)</span></td>
<td align="center"><span class="Italics">8</span></td>
<td align="center"><span class="Italics">8</span></td>
</tr>
<tr>
<td>All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Strokes</span> </td>
<td align="center">1.31 (1.03–1.68)</td>
<td align="center">33</td>
<td align="center">25</td>
</tr>
<tr>
<td><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span></td>
<td align="center"><span class="Italics">1.44 (1.09–1.90)</span></td>
<td align="center"><span class="Italics">26</span></td>
<td align="center"><span class="Italics">18</span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">d</span>
</td>
<td align="center">1.95 (1.43–2.67)</td>
<td align="center">26</td>
<td align="center">13</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td align="center">2.13 (1.45–3.11)</td>
<td align="center">18</td>
<td align="center">8</td>
</tr>
<tr>
<td>Invasive breast cancer<span class="Sup">e</span>
</td>
<td align="center">1.24 (1.01–1.54)</td>
<td align="center">41</td>
<td align="center">33</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td align="center">0.61 (0.42–0.87)</td>
<td align="center">10</td>
<td align="center">16</td>
</tr>
<tr>
<td>Endometrial cancer<span class="Sup">d</span>
</td>
<td align="center">0.81 (0.48–1.36)</td>
<td align="center">6</td>
<td align="center">7</td>
</tr>
<tr>
<td>Cervical cancer<span class="Sup">d</span>
</td>
<td align="center">1.44 (0.47–4.42)</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><span class="Sup">c</span>
</td>
<td align="center">0.67 (0.47–0.96)</td>
<td align="center">11</td>
<td align="center">16</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">d</span>
</td>
<td align="center">0.65 (0.46–0.92)</td>
<td align="center">11</td>
<td align="center">17</td>
</tr>
<tr>
<td>Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">d</span>
</td>
<td align="center">0.71 (0.59–0.85)</td>
<td align="center">44</td>
<td align="center">62</td>
</tr>
<tr>
<td>Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">d</span>
</td>
<td align="center">0.76 (0.69–0.83)</td>
<td align="center">152</td>
<td align="center">199</td>
</tr>
<tr>
<td>Overall Mortality<span class="Sup">f</span>
</td>
<td align="center">1.00 (0.83-1.19)</td>
<td align="center">52</td>
<td align="center">52</td>
</tr>
<tr class="Last">
<td>Global Index<span class="Sup">g</span>
</td>
<td align="center">1.13 (1.02-1.25)</td>
<td align="center">184</td>
<td align="center">165</td>
</tr>
</tbody>
</table>
<p>Timing of the initiation of estrogen therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50-59 years of age, a non-significant trend toward reduced risk for overall mortality <span class="Italics">[HR 0.69 (95 percent CI 0.44-1.07)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd7189322-bd14-4f03-8601-0b50e65db89b"></a><a name="section-13.6.2"></a><p></p>
<h3><span class="Italics">WHI Estrogen-Alone Substudy</span></h3>
<p class="First">The WHI estrogen-alone substudy was stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen alone in predetermined primary endpoints.</p>
<p>Results of the estrogen-alone substudy, which included 10,739 women (average age of 63 years, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other) after an average follow-up of 7.1 years, are presented in <a href="#t11">Table 11</a>.</p>
<a name="G57d3e237-df42-46e4-b711-aed8d26cccec"></a><table border="1" frame="border">
<caption><span>Table 11: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI<span class="Sup">a</span></span></caption>
<colgroup>
<col width="184px">
<col width="152px">
<col width="136px">
<col width="136px">
</colgroup>
<thead valign="bottom"><tr class="Last" valign="bottom">
<th valign="bottom"> </th>
<th valign="bottom">Relative Risk <br>CE vs. Placebo<br>(95% nCI<span class="Sup">b</span>) </th>
<th valign="bottom">CE<br>n = 5,310</th>
<th valign="bottom">Placebo<br>n = 5,429 </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">a</span> Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.<p class="First"><span class="Sup">b</span> Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</p>
<p><span class="Sup">c</span> Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</p>
<p><span class="Sup">d</span> Not included in “global index.?</p>
<p><span class="Sup">e</span> Results are based on an average follow-up of 6.8 years. </p>
<p><span class="Sup">f</span> All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite/probable CHD, PE or cerebrovascular disease.</p>
<p><span class="Sup">g</span> A subset of the events was combined in a “global index? defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes. </p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td>Event</td>
<td> </td>
<td align="center" colspan="2" valign="middle">Absolute Risk per 10,000 <br>Women-Years </td>
</tr>
<tr>
<td>CHD events<span class="Sup">c</span>
</td>
<td align="center">0.95 (0.78–1.16)</td>
<td align="center">54</td>
<td align="center">57</td>
</tr>
<tr>
<td>
<span class="Italics">   Non-fatal MI</span><span class="Sup">c</span>
</td>
<td align="center"><span class="Italics">0.91 (0.73–1.14)</span></td>
<td align="center"><span class="Italics">40</span></td>
<td align="center"><span class="Italics">43</span></td>
</tr>
<tr>
<td><span class="Italics">   CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">c</span></span></td>
<td align="center"><span class="Italics">1.01 (0.71–1.43)</span></td>
<td align="center"><span class="Italics">16</span></td>
<td align="center"><span class="Italics">16</span></td>
</tr>
<tr>
<td>All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span><span class="Sup">c</span>
</td>
<td align="center">1.33 (1.05–1.68)</td>
<td align="center">45</td>
<td align="center">33</td>
</tr>
<tr>
<td><span class="Italics">   Ischemic<span class="Sup">c</span></span></td>
<td align="center"><span class="Italics">1.55 (1.19–2.01)</span></td>
<td align="center"><span class="Italics">38</span></td>
<td align="center"><span class="Italics">25</span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">c,d</span>
</td>
<td align="center">1.47 (1.06–2.06) </td>
<td align="center">23</td>
<td align="center">15</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><span class="Sup">c</span>
</td>
<td align="center">1.37 (0.90–2.07) </td>
<td align="center">14</td>
<td align="center">10</td>
</tr>
<tr>
<td>Invasive breast cancer<span class="Sup">c</span>
</td>
<td align="center">0.80 (0.62–1.04) </td>
<td align="center">28</td>
<td align="center">34</td>
</tr>
<tr>
<td>Colorectal cancer<span class="Sup">e</span>
</td>
<td align="center">1.08 (0.75–1.55)</td>
<td align="center">17</td>
<td align="center">16</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><span class="Sup">c</span>
</td>
<td align="center">0.65 (0.45–0.94)</td>
<td align="center">12</td>
<td align="center">19</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">c,d</span>
</td>
<td align="center">0.64 (0.44–0.93)</td>
<td align="center">11</td>
<td align="center">18</td>
</tr>
<tr>
<td>Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">c,d</span>
</td>
<td align="center">0.58 (0.47–0.72)</td>
<td align="center">35</td>
<td align="center">59</td>
</tr>
<tr>
<td>Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">c,d</span>
</td>
<td align="center">0.71 (0.64–0.80)</td>
<td align="center">144</td>
<td align="center">197</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes<span class="Sup">e,f</span>
</td>
<td align="center">1.08 (0.88–1.32) </td>
<td align="center">53</td>
<td align="center">50</td>
</tr>
<tr>
<td>Overall mortality<span class="Sup">c,d</span>
</td>
<td align="center">1.04 (0.88–1.22) </td>
<td align="center">79</td>
<td align="center">75</td>
</tr>
<tr class="Last">
<td>Global Index<span class="Sup">g</span>
</td>
<td align="center">1.02 (0.92–1.13) </td>
<td align="center">206</td>
<td align="center">201</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI “global index? that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> while the absolute risk reduction per 10,000 women-years was 7 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.<span class="Sup">9</span> The absolute excess risk of events included in the “global index? was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality <span class="Italics">[see <a href="#s2">Boxed Warnings</a>, and Warnings and Precautions (</span><span class="Italics"><a href="#G6b9182cc-a83e-4358-b088-927762dd73b2">5</a></span><span class="Italics">)]</span>.</p>
<p>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years.</p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtype or severity, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess risk was present in all subgroups of women examined, see <a href="#G3afc5cc2-6050-4503-8c08-02bdc5dee765">Table 10</a>.<span class="Sup">10</span></p>
<p>Timing of the initiation of estrogen therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age showed in women 50-59 years of age, a non-significant trend toward reduced risk for CHD [HR 0.63 (95 percent CI 0.36-1.09)] and overall mortality <span class="Italics">[HR 0.71 (95 percent CI 0.46-1.11)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gc7c4bb5d-1fd2-4ae5-8246-2df55cd4f899"></a><a name="section-13.7"></a><p></p>
<h2>14.7 Women's Health Initiative Memory Study</h2>
<p class="First">The estrogen plus progestin Women's Health Initiative Memory Study (WHIMS), an ancillary study of WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age; 35 percent were 70 to 74 years of age; and 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo. </p>
<p>After an average follow-up of 4 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE (0.625 mg) plus MPA (2.5 mg) versus placebo was 2.05 (95 percent CI 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE (0.625 mg) plus MPA (2.5 mg) versus placebo was 45 versus 22 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer’s disease (AD), <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>), and Use in Specific Populations (<a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a>)]</span>.</p>
<p>The WHIMS estrogen-alone ancillary study of WHI, enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age and older (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo.</p>
<p>After an average follow-up of 5.2 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer’s disease (AD), <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the treatment and placebo groups was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>), and Use in Specific Populations (<a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a>)]</span>.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>), and Use in Special Populations (<a href="#Gbc11ba00-fb03-4c51-b24f-c68292c02926">8.5</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="G9932f416-3d1a-4ca7-ba93-78a3536713ce"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span>. <span class="Italics">JAMA</span>. 2007;297:1465-1477.</li>
<li>Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. <span class="Italics">Arch Int Med.</span> 2006;166:357-365.</li>
<li>Cushman M, et al. Estrogen Plus Progestin and Risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span>. <span class="Italics">JAMA</span>. 2004;292:1573-1580.</li>
<li>Curb JD, et al. <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span> and Conjugated Equine Estrogen in Women Without a Uterus. <span class="Italics">Arch Int Med</span>. 2006;166:772-780.</li>
<li>Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. <span class="Italics">JAMA</span>. 2003;289:3234-3253.</li>
<li>Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. <span class="Italics">JAMA</span>. 2006;295:1647-1657.</li>
<li>Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. <span class="Italics">JAMA</span>. 2003;290:1739-1748. </li>
<li>Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> and Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> in Postmenopausal Women. <span class="Italics">JAMA</span>. 2004;291:2947-2958.</li>
<li>Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> and BMD in Postmenopausal Women With Hysterectomy: Results From the Women’s Health Initiative Randomized Trial. <span class="Italics">J Bone Miner Res</span>. 2006;21:817-828.</li>
<li>Hendrix SL, et al. Effects of Conjugated Equine Estrogen on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in the Women’s Health Initiative. <span class="Italics">Circulation</span>. 2006;113:2425-2434.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="G7e6bb2ba-6c05-4135-a99b-e6db70e8c291"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="G873c3b0f-f415-4089-9963-e7aeae7f435a"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied </h2>
<p class="First">PREMPRO therapy consists of a single tablet to be taken once daily. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="G60108f4f-516c-4d52-b674-2fdd3c45f04e"></a><a name="section-15.1.1"></a><p></p>
<h3><span class="Bold">PREMPRO 0.625 mg/5 mg</span></h3>
<p class="First"></p>
<p></p>
<p><span class="Bold">PREMPHASE</span> therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28. </p>
<p>NDC 54868-3800-0, carton includes 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card containing 28 tablets (14 oval, maroon Premarin tablets and 14 oval, light-blue tablets). </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G95ef984d-7c77-476f-8a59-719cfdd3ae0a"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First"><span class="Bold">Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="G294e9daa-da18-414a-8026-96c165ab8895"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See Section <a href="#G474ffdce-58f3-46f7-be1f-c967a3f51f6f">17.4</a> for FDA-Approved Patient Labeling.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Gf4367b07-d1d7-4250-a1d2-64a2b588f027"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></h2>
<p class="First">Inform postmenopausal women of the importance of reporting abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare provider as soon as possible <span class="Italics">[see Warnings and Precautions (<a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd23f6f0a-e1f9-40a3-b7fc-e3016cfbd539"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Possible Serious Adverse Reactions With Estrogen Plus Progestin Therapy</h2>
<p class="First">Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestin therapy including <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, Malignant Neoplasms, and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> <span class="Italics">[see Warnings and Precautions <a href="#G4a357322-b1d8-4c07-b3fc-9b870b5eabef">(5.1</a>, <a href="#Gdc16a52e-8a04-4cc6-8d43-09aa530591a4">5.2</a>, <a href="#G30aad6c8-10b4-4bee-b479-27fe6299a518">5.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G4e77c88a-4a93-4503-82d5-3a9628b49d0c"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Possible Less Serious But Common Adverse Reactions With Estrogen Plus Progestin Therapy</h2>
<p class="First">Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestin therapy such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G474ffdce-58f3-46f7-be1f-c967a3f51f6f"></a><a name="section-16.4"></a><p></p>
<h2>17.4 FDA-Approved Patient Labeling</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="G39629e49-0d2f-4ee7-be74-93a361161f78"></a><a name="section-17"></a><p></p>
<p class="First">PREMPRO<span class="Sup">®</span></p>
<p>(Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) </p>
<p>PREMPHASE<span class="Sup">®</span></p>
<p>(Conjugated Estrogens plus Medroxyprogesterone Acetate Tablets) </p>
<p>Read this PATIENT INFORMATION before you start taking PREMPRO or PREMPHASE and read what you get each time you refill your PREMPRO or PREMPHASE prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. </p>
<div class="Warning">
<a name="G5756f3a5-7368-4a75-81a9-126a1e9f996b"></a><a name="section-17.1"></a><p></p>
<p class="First"><span class="Bold">What is the most important information I should know about PREMPRO and PREMPHASE (combinations of estrogens and a progestin)?</span></p>
<ul class="Disc">
<li>Do not use estrogens with progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (decline of brain function)</li>
<li>Using estrogens with progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, or blood clots</li>
<li>Using estrogens with progestins may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women age 65 years or older</li>
<li>Do not use estrogen-alone to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></li>
<li>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb)</li>
<li>Using estrogen-alone may increase your chances of getting <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or blood clots</li>
<li>Using estrogen-alone may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women age 65 years or older</li>
<li>You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G280553b8-932a-4d15-8b62-9c043ca78b56"></a><a name="section-17.1"></a><p></p>
<p class="First"><span class="Bold">What is PREMPRO or PREMPHASE?</span></p>
<p>PREMPRO or PREMPHASE are medicines that contain two kinds of hormones, estrogens and a progestin. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="Gcc2074bf-6a35-4385-be55-a173a367f204"></a><a name="section-17.1.1"></a><p></p>
<h3><span class="Bold">PREMPRO or PREMPHASE is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</span></h3>
<ul class="Disc">
<li>
<span class="Bold">Reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span></span><p class="First">Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the “change of life? or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes “surgical <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.? </p>
<p>When the estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (“hot flashes? or “hot flushes?). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. </p>
</li>
<li>
<span class="Bold">Treat menopausal changes in and around the vagina</span><p class="First">You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE to control these problems. If you use PREMPRO or PREMPHASE only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you. </p>
</li>
<li>
<span class="Bold">Help reduce your chances of getting <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (thin weak bones)</span><p class="First"><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> is a thinning of the bones that makes them weaker and easier to break. If you use PREMPRO or PREMPHASE only to prevent <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. Weight-bearing exercise, like walking or running, and taking calcium (1500 mg/day of elemental calcium) and vitamin D (400-800 IU/day) supplements may also lower your chances of getting postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. It is important to talk about exercise and supplements with your healthcare provider before starting them. </p>
<p>You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE. </p>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G13f675c7-79c9-48ec-90f2-ff0f646ace22"></a><a name="section-17.1.2"></a><p></p>
<h3><span class="Bold">Who should not take PREMPRO or PREMPHASE?</span></h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gca81172f-2d8f-4b96-9ba5-740b26db6592"></a><a name="section-17.1.3"></a><p></p>
<h3><span class="Bold">Do not take PREMPRO or PREMPHASE if you have had your uterus (womb) removed (hysterectomy).</span></h3>
<p class="First">PREMPRO and PREMPHASE contain a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not take PREMPRO or PREMPHASE. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ga206de08-f887-47ae-9fbf-c8509d0e7329"></a><a name="section-17.1.4"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gbaa6f983-7dc0-4fb5-a9c8-622f22b1e0e4"></a><a name="section-17.1.5"></a><p></p>
<h3><span class="Bold">Do not take PREMPRO or PREMPHASE if you:</span></h3>
<ul class="Disc">
<li><span class="Bold">Have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></li>
<li>
<span class="Bold">Currently have or have had certain cancers</span><p class="First">Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. </p>
<p>If you have or have had cancer, talk with your healthcare provider about whether you should use PREMPRO or PREMPHASE. </p>
</li>
<li><span class="Bold">Had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></span></li>
<li><span class="Bold">Currently have or have had blood clots</span></li>
<li><span class="Bold">Currently have or have had liver problems</span></li>
<li><span class="Bold">Have been diagnosed with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder</span></li>
<li>
<span class="Bold">Are allergic to PREMPRO or PREMPHASE or any of their ingredients</span><p class="First">See the <a href="#s80">end of this leaflet</a> for a list of ingredients in PREMPRO and PREMPHASE. </p>
</li>
<li><span class="Bold">Think you may be pregnant</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G5671f469-a3af-462b-abd1-24968602ed19"></a><a name="section-17.1.6"></a><p></p>
<h3><span class="Bold">Tell your healthcare provider</span></h3>
<ul class="Disc">
<li>
<span class="Bold">If you have any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span><p class="First"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</p>
</li>
<li>
<span class="Bold">About all of your medical problems</span><p class="First">Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. </p>
</li>
<li>
<span class="Bold">About all the medicines you take</span><p class="First">This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how PREMPRO or PREMPHASE works. PREMPRO or PREMPHASE may also affect how your other medicines work. </p>
</li>
<li>
<span class="Bold">If you are going to have surgery or will be on bedrest</span><p class="First">You may need to stop taking estrogens and progestins. </p>
</li>
<li>
<span class="Bold">If you are breastfeeding</span><p class="First">The hormones in PREMPRO and PREMPHASE can pass into your milk.</p>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G6a24bc8c-14c6-4011-b17d-d65b863e48c0"></a><a name="section-17.1.7"></a><p></p>
<h3><span class="Bold">How should I take PREMPRO or PREMPHASE?</span></h3>
<ul class="Disc">
<li>Take one PREMPRO or PREMPHASE tablet at the same time each day</li>
<li>If you miss a dose, take it as soon as possible<p class="First">If it is almost time for your next dose, skip the missed dose and go back to your normal schedule. Do not take 2 doses at the same time. </p>
</li>
<li>Estrogens should be used at the lowest dose possible for your treatment only as long as needed<p class="First">You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with PREMPRO or PREMPHASE. </p>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gae4179b6-bc5f-4f8c-8453-c75cc2739032"></a><a name="section-17.1.8"></a><p></p>
<h3><span class="Bold">What are the possible side effects of PREMPRO or PREMPHASE?</span></h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G4ac32742-c51f-4b2d-abd5-b6bb6b06776e"></a><a name="section-17.1.9"></a><p></p>
<h3><span class="Bold">Side effects are grouped by how serious they are and how often they happen when you are treated.</span></h3>
<p class="First"><span class="Bold">Serious, but less common side effects: </span></p>
<ul class="Disc">
<li>Breast cancer </li>
<li>Cancer of the uterus </li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> </li>
<li>Blood clots </li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span> </li>
<li>Ovarian cancer </li>
<li>High blood pressure</li>
<li>Liver problems</li>
<li>High blood sugar</li>
<li>Enlargement of benign tumors of the uterus (“fibroids?)</li>
<li>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G7d92a424-f953-4e18-ba3f-9935d6cf7cd6"></a><a name="section-17.1.10"></a><p></p>
<h3><span class="Bold">Some of the warning signs of these serious side effects include:</span></h3>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> </li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness </li>
<li>Changes in speech </li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> </li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs </li>
<li>Changes in vision </li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </li>
<li>Yellowing of the skin, eyes or nail beds</li>
</ul>
<p class="First">Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptoms that concern you. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G2c0b6f10-22f5-4220-a94f-5118d645db87"></a><a name="section-17.1.11"></a><p></p>
<h3><span class="Bold">Less serious, but common side effects include:</span></h3>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span> </li>
<li>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting </li>
<li>Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>/<span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></li>
<li>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></li>
</ul>
<p class="First">These are not all the possible side effects of PREMPRO or PREMPHASE. For more information, ask your healthcare provider or pharmacist for advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gbd22f8df-b099-4261-b5fa-22307b9b01ab"></a><a name="section-17.1.12"></a><p></p>
<h3><span class="Bold">What can I do to lower my chances of getting a serious side effect with PREMPRO or PREMPHASE?</span></h3>
<ul class="Disc">
<li>Talk with your healthcare provider regularly about whether you should continue taking PREMPRO or PREMPHASE</li>
<li>See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking PREMPRO or PREMPHASE</li>
<li>Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else<p class="First">If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast exams more often. </p>
</li>
<li>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances for getting heart disease<p class="First">Ask your healthcare provider for ways to lower your chances of getting heart disease. </p>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G4f7906e3-d3c7-4d72-9484-d24fb9ab5136"></a><a name="section-17.1.13"></a><p></p>
<h3><span class="Bold">General Information about the safe and effective use of PREMPRO and PREMPHASE</span></h3>
<p class="First">Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take PREMPRO or PREMPHASE for conditions for which it was not prescribed. Do not give PREMPRO or PREMPHASE to other people, even if they have the same symptoms you have. It may harm them. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd5dbd46b-ebd1-439b-94a9-b1d1c7bfc01b"></a><a name="section-17.1.14"></a><p></p>
<h3><span class="Bold">Keep PREMPRO and PREMPHASE out of the reach of children.</span></h3>
<p class="First">This leaflet provides a summary of the most important information about PREMPRO and PREMPHASE. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about PREMPRO and PREMPHASE that is written for health professionals by calling the toll free number 800-934-5556.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-17.1.15"></a><p></p>
<h3><span class="Bold">What are the ingredients in PREMPRO and PREMPHASE?</span></h3>
<p class="First">PREMPRO contains the same conjugated estrogens found in Premarin, which are a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol and 17β-dihydroequilin. PREMPRO also contains either 1.5, 2.5, or 5 mg of medroxyprogesterone acetate. </p>
<p>PREMPRO 0.3 mg/1.5 mg, 0.45 mg/1.5 mg, and 0.625 mg/2.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, lactose monohydrate, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, povidone, titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.</p>
<p>PREMPRO 0.625 mg/5 mg tablets also contain calcium phosphate tribasic, calcium sulfate, carnauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylene glycol, sucrose, povidone, titanium dioxide, FD&amp;C Blue No. 2, and black iron oxide.</p>
<p>PREMPHASE is two separate tablets. One tablet (maroon color) is 0.625 mg of Premarin, which is a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17 α-dihydroequilin, 17 α-estradiol and 17 β-dihydroequilin. The maroon tablet also contains calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, titanium dioxide, FD&amp;C Blue No. 2, FD&amp;C Red No. 40. The second tablet (light-blue color) contains 0.625 mg of the same ingredients as the maroon color tablet plus 5 mg of medroxyprogesterone acetate. The light-blue tablet also contains calcium phosphate tribasic, calcium sulfate, carnauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylene glycol, sucrose, povidone, titanium dioxide, FD&amp;C Blue No. 2, and black iron oxide. </p>
<p>PREMPRO therapy consists of a single tablet to be taken once daily. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G59fc7311-7580-4270-bac4-90cc7164f1ab"></a><a name="section-17.1.16"></a><p></p>
<h3><span class="Bold">PREMPRO 0.3 mg/1.5 mg</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card - Each carton includes 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card containing 28 oval, cream tablets. Each tablet contains 0.3 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G6d3c5363-e071-498b-8204-3a931af4202b"></a><a name="section-17.1.17"></a><p></p>
<h3><span class="Bold">PREMPRO 0.45 mg/1.5 mg</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card - Each carton includes 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card containing 28 oval, gold tablets. Each tablet contains 0.45 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd799fd51-3d21-4255-ba19-3c421e102d31"></a><a name="section-17.1.18"></a><p></p>
<h3><span class="Bold">PREMPRO 0.625 mg/2.5 mg</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card - Each carton includes 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card containing 28 oval, peach tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 2.5 mg of medroxyprogesterone acetate for oral administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G69655ebc-80e2-4a9f-bab9-56a4841d76f8"></a><a name="section-17.1.19"></a><p></p>
<h3><span class="Bold">PREMPRO 0.625 mg/5 mg</span></h3>
<p class="First">EZ DIAL<span class="Sup">®</span> dispenser - Each carton includes 3 EZ DIAL dispensers containing 28 tablets. One EZ DIAL dispenser contains 28 oval, light-blue tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration. </p>
<p><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card - Each carton includes 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card containing 28 oval, light-blue tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration. </p>
<p>PREMPHASE therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28. </p>
<p>Each carton includes 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack containing 28 tablets. One <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack contains 14 oval, maroon Premarin tablets containing 0.625 mg of conjugated estrogens and 14 oval, light-blue tablets that contain 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration. </p>
<p>The appearance of PREMPRO tablets is a trademark of Wyeth Pharmaceuticals. </p>
<p>The appearance of PREMARIN tablets is a trademark of Wyeth Pharmaceuticals. The appearance of the conjugated estrogens/medroxyprogesterone acetate combination tablets is a trademark. </p>
<p><span class="Bold">Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="G3f675c5a-45ed-4a5a-8bcc-3d1a7654b8e3"></a><a name="section-18"></a><p></p>
<a name="G08a6d01b-37bf-4102-adec-623c4ee55892"></a><table border="1" frame="border">
<colgroup>
<col width="56px">
<col width="500px">
<col width="60px">
</colgroup>
<tbody class="Headless"><tr class="First Last">
<td><img alt="computer_13.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=computer.jpg"></td>
<td>This product's label may have been updated. For current package insert and further product information, please visit www.pfizerpro.com or call our medical communications department toll-free at 1‑800‑934‑5556. </td>
<td><img alt="phone_7.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=phone.jpg"></td>
</tr></tbody>
</table>
<div class="Figure"><img alt="pfizer-logo-black.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=pfizer-logo-black.jpg"></div>
<p class="First">LAB-0502-2.0</p>
<p>Rev 05/11</p>
<p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18.1"></a><p></p>
<p class="First">Distributed by:<br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma      74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Gd34d08f3-4ba6-4a68-9995-2c68807428c1"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 0.625 mg / 5 mg - CARTON</span></p>
<p>NDC 54868-3800-0</p>
<p>Package contains 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card of 28 tablets</p>
<p>PREMPHASE<span class="Sup">®</span></p>
<p>(conjugated estrogens/medroxyprogesterone acetate tablets)</p>
<p>14 maroon tablets of 0.625 mg conjugated estrogens</p>
<p>14 light-blue tablets of 0.625 mg conjugated estrogens/5 mg medroxyprogesterone acetate</p>
<p>Rx only</p>
<p></p>
<div class="Figure"><img alt="No Label Available for 0.625 mg / 5 mg " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=701acf2c-fffe-451a-9b94-82d825e5a47c&amp;name=No%20Label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PREMPHASE 		
					</strong><br><span class="contentTableReg">conjugated estrogens and medroxyprogesterone acetate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3800(NDC:0046-2579)</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3800-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">14 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">14 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>PREMPRO 		
					</strong><br><span class="contentTableReg">conjugated estrogens and medroxyprogesterone acetate tablet, sugar coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED</strong> (ESTROGENS, CONJUGATED) </td>
<td class="formItem">ESTROGENS, CONJUGATED</td>
<td class="formItem">0.625 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>MEDROXYPROGESTERONE ACETATE</strong> (MEDROXYPROGESTERONE) </td>
<td class="formItem">MEDROXYPROGESTERONE ACETATE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (100 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (LIGHT BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;0625;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020527</td>
<td class="formItem">12/01/1995</td>
<td class="formItem">06/30/2010</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>PREMARIN 		
					</strong><br><span class="contentTableReg">conjugated estrogens tablet, sugar coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED</strong> (ESTROGENS, CONJUGATED) </td>
<td class="formItem">ESTROGENS, CONJUGATED</td>
<td class="formItem">0.625 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (MAROON) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PREMARIN;0625</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020527</td>
<td class="formItem">12/01/1995</td>
<td class="formItem">06/30/2010</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075796</td>
<td class="formItem">07/08/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-3800)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cd8751c0-81b3-4fc4-84bf-1f84e0a827b5</div>
<div>Set id: 701acf2c-fffe-451a-9b94-82d825e5a47c</div>
<div>Version: 2</div>
<div>Effective Time: 20121126</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
